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Abstract 
Molecular and Cellular Mechanisms Regulating PTH Receptor Signaling and Biology 
 
Alex Duncan White, PhD 
 
University of Pittsburgh, 2020 
 
 
 
 
 G protein-coupled receptors (GPCRs) are the largest family of cell surface proteins that 
initiate intracellular signaling in response to extracellular stimuli.  The classical paradigm of GPCR 
signaling dictates that downstream responses are relatively transient and confined to the cell 
surface, but this notion has been challenged in recent years following the identification of several 
receptors that can engage in sustained G protein-dependent signaling responses from early 
endosomes following internalization of the ligand-receptor complex.  This phenomenon was 
initially discovered for the parathyroid hormone (PTH) type 1 receptor (PTHR), a class B GPCR 
that mediates the biological effects of endogenous peptide ligands PTH and its related peptide 
(PTHrP).  Despite significant advancements toward understanding the determinants and relevance 
of PTHR-mediated endosomal cAMP signaling, this aspect of GPCR signaling remains 
incompletely understood.  Here, we utilize a combination of optical, biochemical, cell biological, 
and physiological approaches to elucidate novel molecular and cellular mechanisms that underlie 
endosomal cAMP responses by the PTHR, as well as its biological relevance.  We demonstrate 
that extracellular Ca2+ acts as a positive allosteric modulator of the PTHR by prolonging ligand 
residence time and increasing the propensity of ligand-receptor complexes to engage in endosomal 
cAMP generation.  We subsequently utilize biased agonism to decode the biological information 
encoded in the spatial versus temporal dimension of cAMP signaling.  Finally, we identify Gq 
coupling as a critical determinant in PTH-mediated endosomal cAMP production.  These findings 
 v 
unveil novel insights into mechanisms and biological outcomes of PTHR-mediated signaling that 
may prove useful in rational drug design. 
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1.0 Introduction 
1.1 G Protein-coupled Receptors 
G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors that 
regulate an array of physiological processes in response to extracellular stimuli.  They consist of 
an extracellular amino terminus, seven transmembrane (TM) helices, and an intracellular carboxy 
terminus, and these receptors are highly conserved and represent approximately 1-2% of the 
human genome.  The evolution of multicellular organisms has been partly dependent on the 
successful evolution of GPCRs, being able to transduce extracellular signals to intracellular 
functions, and thus, enabling cells to communicate with each other and their environment [1].  
GPCRs are also present in insects [2], plants [3], yeast [4], and protozoa [5], as well as in 
nematodes with the C. elegans genome encoding more than 1000 GPCRs [6].  In humans, GPCR 
function is implicated in the regulation of various physiological systems and their malfunction 
causes severe disease states such as cancer, pain, cardiovascular disorders, gastrointestinal 
disorders, and conditions of the central nervous and endocrine systems, among others.  The 
generation of cell-based functional assays in combination with traditional radioligand binding 
assays and the novel structural information derived from crystal structures of several GPCRs are 
enabling the translation of fundamental biology into therapeutic applications [7].  Additionally, 
the cell membrane localization of GPCRs and the diversity of tissue expression have made GPCRs 
ideal pharmacological targets for drug development.  Not surprisingly, around 30% of FDA-
approved therapeutics target GPCRs, and there persists a growing interest in this large family of 
receptors both within the pharmaceutical industry and academia.   
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1.1.1 Classification of GPCRs 
GPCRs in humans are generally classified into five families based on the GRAFS 
classification system that are based on phylogenetic analyses [8]:  Glutamate receptor family (G), 
rhodopsin family (R), adhesion receptor family (A), frizzled/taste 2 receptor family (F), and 
secretin receptor family (S).   
The glutamate receptor family (formerly class C) is most commonly associated with 
metabotropic glutamate receptors, Ca2+-sensing receptor, γ-aminobutyric acid B receptors, and 
type I taste receptors.  The N-terminus of these GPCRs is quite large and contains the ligand 
recognition domain generated by forming two lobes separated by a cavity in which ligands bind to 
produce the “Venus fly trap” or VFT domain.  The VFT domain may also accommodate allosteric 
binding sites and is connected with the 7-TM core through a cysteine-rich domain, which also 
plays a role in receptor activation. 
 The rhodopsin family (formerly class A) is comprised of more than 700 receptors that share 
high sequence similarity [9] and several structural characteristics with rhodopsin, including an 
NPXXY motif on TM helix 7 and a DRY motif between TM3 and intracellular loop 2 (ICL2) [10].  
Ligand binding for receptors in this class typically takes place within a cavity formed between TM 
helices.  Notable GPCRs in this class that hold significant physiological relevance include 
muscarinic acetylcholine receptors, dopamine receptors, adrenergic receptors, opioid receptors, 
adenosine receptors, and histamine receptors.   
 The adhesion family has recently attracted much attention due to several unique features.  
These receptors typically possess long N-termini that contain an abundance of serine and threonine 
residues that constitute sites for O- and N-glycosylation, which act as mucin-like domains to create 
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rigid structures that protrude from the cell surface.  Additionally, many receptors in this family 
contain a proteolytic domain in their N-termini. 
 The frizzled/taste 2 receptor family is far less understood as compared to other classes, and 
their similarity is largely confined to results from phylogenetic analysis.  Only recently have 
frizzled receptors been established as true GPCRs following reports that binding of Wnt ligand 
can induce G protein coupling.  Frizzled receptors are characterized by long N-termini with 
conserved cysteine residues that are considered critical for Wnt binding.   
 The secretin family (formerly class B) consists of receptors that have rather long N-termini 
that contain conserved disulfide bridges formed by cysteine residues, and these N-termini are 
considered paramount for ligand binding.  Secretin receptors are perhaps best well known for 
binding relatively large peptide ligands that often, but not always, act in a paracrine manner.  There 
are currently 15 identified members of this family in humans, including the parathyroid hormone 
type 1 receptor that serves as the focus of the dissertation work herein.   
1.1.2 GPCR Signaling    
Ligand binding induces conformational changes within the receptor that permit coupling to 
intracellular transducer proteins, including G proteins, GPCR kinases (GRKs), and β-arrestins 
(βarrs).  G proteins are heterotrimeric complexes comprised of one α, β, and γ subunits when in 
the GDP-bound form [11].  Receptor activation leads to exchange of GDP for GTP on the Gα 
subunit and its dissociation from the Gβγ obligate heterodimer, with subsequent modulation of 
second messenger pathways and other downstream effectors.  The intrinsic GTPase activity of the 
Gα subunit hydrolyzes GTP into GDP, leading to reassociation of subunits into the inactive 
heterotrimeric complex [12].  There are four main classes of Gα subunits that have been identified 
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based on sequence similarity [13]:  Gs that stimulates adenylyl cyclase activity to increase 
intracellular cyclic adenosine monophosphate (cAMP) levels; Gi/o that inhibits adenylyl cyclase 
activity; Gq/11 that leads to an increase in intracellular Ca
2+ levels via activation of phospholipase 
C (PLC) β; and G12/13 that regulates Rho guanine nucleotide exchange factors.   
These signals are terminated by the collective work of GRKs, βarrs, and cellular endocytic 
machinery.  Activated GPCRs recruit GRKs that phosphorylate serine and threonine residues 
within the receptor’s third intracellular loop (ICL3) and C-terminal tail 
1.2 The Parathyroid Hormone Type 1 Receptor 
The parathyroid hormone (PTH) type 1 receptor (PTHR) is a class B GPCR that is expressed 
in a variety of tissues, predominantly in bone (osteoblasts and osteocytes), the kidney (proximal 
and distal tubules), and mammary glands [14]. The PTHR serves as the cognate receptor for 
endogenous peptide ligands PTH and its related peptide (PTHrP), which act in an endocrine and 
paracrine manner, respectively, to exert distinct biological effects. While PTH is associated with 
homeostatic control of serum Ca2+, phosphate, and active vitamin D concentrations, PTHrP 
primarily regulates growth and development of bone, heart, mammary glands, and other tissues. 
Additionally, both ligands are implicated in dynamic bone remodeling processes, mediating both 
anabolic and catabolic actions. PTH and PTHrP exert their effects primarily via Gs/cAMP/protein 
kinase A (PKA) and Gq/PLC/PKC signaling pathways. 
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1.2.1 Biological Effects of the PTHR 
PTH is secreted as an 84-amino acid peptide that serves as the primary regulator of ionized 
serum Ca2+ levels.  In response to hypocalcemic conditions when Ca2+ concentration falls below 
the homeostatic set point in blood, or approximately 1.2 ± 0.1 mM, PTH is secreted from the 
parathyroid glands and acts in an endocrine fashion by exerting effects on specific bone and kidney 
cells.  In bone, PTH-mediated activation of the PTHR expressed by osteoblasts and osteocytes 
ultimately promotes bone matrix resorption and liberation of Ca2+ into the systemic circulation 
[15-18].  In the kidneys, PTH increases Ca2+ reabsorption by distal tubule cells by modulating 
expression and activity of Ca2+ transport proteins [19, 20].  Concomitant with this effect of PTH 
is a decrease in inorganic phosphate reabsorption in proximal tubule cells via reduction of cell 
surface sodium-dependent phosphate transporters [21-23], which ensures that Ca2+ remains in the 
ionized state.  PTH also acts on renal proximal tubule cells to increase circulating levels of active 
vitamin D3 via upregulation of the 25-hydroxyvitamin D3 1α-hydroxylase, and active vitamin D3 
subsequently serves to increase absorption of Ca2+ from the gastrointestinal tract.   
PTHrP is secreted as a 141-amino acid peptide that is capable of inducing analogous effects 
on bone and kidney cells observed for PTH, which is not surprising given the shared amino acid 
sequence homology within the N-terminal region of these peptides that has been shown to be 
critical for activity [24-26].  While it was originally associated as a factor responsible for the 
hypercalcemia frequently observed in cancer patients, PTHrP is now recognized to play a role in 
the growth and development of a variety of tissues, including bone [27], mammary glands [28], 
and teeth [29]. 
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1.3 New Mode of cAMP Signaling 
In the classical model of GPCR signaling, G protein-dependent signaling by activated 
receptor is terminated following phosphorylation by GRKs of intracellular receptor domains and 
recruitment of βarrs, which both sterically occlude G protein binding and promote endocytosis of 
ligand-bound GPCRs.  Thus, signaling responses by these receptors were initially considered 
transient in nature and confined to the plasma membrane; however, this model has been challenged 
in recent years by the discovery of GPCRs that can mediate sustained signaling from early 
endosomes following internalization of the ligand-receptor complex [30, 31].  This unexpected 
aspect of GPCR signaling has been intensely investigated in the context of the PTHR due to the 
apparent ligand-dependent nature of endosomal signaling by this receptor.  Notably, while 
PTHrP(1-36) induces only transient cAMP responses from the cell surface that are consistent with 
the classical model of GPCR signaling, binding of PTH(1-34) and various long-acting analogs 
promote sustained cAMP generation that arises from ligand-receptor complexes that remain active 
in early endosomes [31]. 
 Studies involving the PTHR have provided ample evidence that maintenance of sustained 
Gs signaling from subcellular compartments is dependent upon ligand-specific stabilization of 
particular active receptor conformations.  In the classical GPCR signaling paradigm, high-affinity 
ligand binding states were believed to exist only upon G protein coupling to the receptor [32].  The 
PTHR deviates from this model, as this receptor has been shown to form high-affinity complexes 
in the absence of G protein coupling with PTH and other long-acting ligands [33, 34].  In contrast, 
PTHrP only forms such complexes in the context of G protein coupling, and these complexes 
undergo rapid dissociation in the presence of GTPγS, a guanine nucleotide analog that induces G 
protein uncoupling from the receptor.  These findings led to the hypothesis that the PTHR adopts 
 7 
at least two distinct active conformations:  RG and R0.  Accordingly, whereas the RG conformation 
stabilized by PTHrP is G protein-dependent and is associated with transient cAMP responses from 
the cell surface, the R0 state is not altered by G protein coupling but nevertheless permits sustained 
cAMP generation following internalization of the receptor [31, 35-37]. 
1.3.1 Mechanisms of PTHR Endosomal cAMP Signaling and its Regulation 
Sustained cAMP production in response to PTH is initiated by binding of βarrs to activated 
receptor.  Whereas βarr is most commonly associated with inhibition of G protein coupling, 
previous studies have shown that βarrs contribute to prolonged PTHR-mediated sustained cAMP 
responses by forming ternary complexes with activated receptor and Gβγ subunits [38].  Indeed, 
kinetic and biochemical approaches have indicated that the PTHR-Gβγ-βarr complex in 
endosomes provides a scaffold by which Gs activation is accelerated, leading to prolonged cAMP 
generation by PTH-bound receptor.  This conclusion is supported by additional mutation analyses 
that have shown that the site of interaction of Gβγ subunits with the receptor does not overlap with 
that of βarr [39]. 
 In addition to the role of forming these ternary complexes, βarrs have also been implicated 
in downstream regulation of PTHR endosomal cAMP production.  It is well-established that βarrs 
have the capacity to activate extracellular signal-regulated kinases (ERK), which, in turn, can lead 
to phosphorylation and inhibition of cAMP-specific phosphodiesterase (PDE4) enzymatic activity 
[40].  The Vilardaga lab has previously reported that endosomal cAMP responses by PTH are 
prolonged when cells are treated with PDE4 inhibitors but blunted when cells are treated with 
inhibitors of ERK1/2 [41], suggesting a positive feedback loop whereby PTHR-βarr complexes 
induce ERK1/2 signaling from endosomes to promote sustained cAMP generation. 
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Termination of sustained cAMP responses by the PTHR is predominantly controlled by 
mechanisms instilled within the endosomal trafficking pathway.  Previous work has highlighted 
that the release of βarrs from the PTHR localized in endosomes is concomitant with association of 
the retromer complex with the receptor [41].  The retromer complex is comprised of two 
membrane-bound sorting nexins (SNX1 and SNX2) as well as a heterotrimer consisting of vesicle 
protein sorting (Vps) 26, 29, and 35, which collectively serve to regulate the sorting of cargo 
proteins from early endosomes to the trans-Golgi network [42, 43].  Examination of this complex 
in the context of PTHR-mediated cAMP showed that overexpression of Vps subunits reduces the 
duration of cAMP generation, whereas siRNA targeting of the subunits prolonged cAMP signaling 
time courses [41].  This process was recently shown to be dependent upon PKA activation and 
subsequent v-ATPase phosphorylation and endosomal acidification, which promotes dissociation 
of active PTH-PTHR-βarr complexes and the assembly of inactive PTHR-retromer complexes 
[44].   
1.3.2 Physiological and Disease Relevance of Endosomal cAMP Signaling 
PTH and PTHrP are implicated in bone remodeling processes, mediating both anabolic and 
catabolic effects, but previous studies have shown that PTH(1-34) stimulates more prolonged 
increases in serum levels of 1,25-dihydroxy-vitamin D, Ca2+, and bone resorption markers than 
does PTHrP(1-36) when the ligands are injected by continuous infusion [45-47].  The anabolic 
effects of the PTHR on bone have led to its clinical targeting for the treatment of osteoporosis by 
once daily subcutaneous injection of the FDA-approved agents PTH(1-34) (teriparatide) [48] or 
abaloparatide (ABL) [49], a modified PTHrP(1-34) analog.  While PTH and ABL stimulate 
transient cAMP production derived from ligand-receptor complexes at the plasma membrane, only 
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PTH causes sustained signaling via the internalization of PTHR in complex with βarr and Gβγ 
subunits.  Observation that ABL can stimulate bone anabolic responses that are comparable with 
those induced by PTH but with a significantly reduced hypercalcemic effect led to the hypothesis 
that transient cAMP production from the cell surface might favor the formation of new bone, while 
sustained cAMP production from endosomes may promote bone breakdown.  In agreement with 
this hypothesis, previous studies have shown that a modified PTH/PTHrP chimera that triggers 
substantially longer endosomal cAMP responses than PTH also induces enhanced and prolonged 
blood Ca2+ elevation in mice and monkeys compared to PTH [36, 50].  This link is further 
strengthened by a recent study demonstrating that chronic hypocalcemia in patients with idiopathic 
hypoparathyroidism can be caused by a single point mutation in residue 25 of PTH that fails to 
engage in endosomal cAMP [51, 52].  Implicit in these observations is that endosomal cAMP 
production in PTHR signaling has both physiological and disease relevance. 
 
1.4 Advancing our Understanding of Endosomal cAMP Regulation and Significance 
Since its initial discovery, significant advancements have been made toward elucidating the 
molecular and cellular determinants that underlie PTHR endosomal cAMP and its biological 
outcomes.  Even so, several outstanding questions remain regarding this unexpected aspect of 
GPCR signaling.  Are there extracellular factors that regulate the propensity of ligand-receptor 
complexes to engage in endosomal cAMP production?  What ligand-dependent determinants exist 
that dictate spatiotemporal regulation of cAMP responses?  What biological information is 
encoded within the spatial versus temporal dimension of cAMP signaling?  Are there additional 
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intracellular transducer proteins that can modulate this process?  Here, we utilize a combination of 
optical, biochemical, cell biological, and physiological approaches to address each of these 
questions. 
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2.0 Ca2+ Allostery in PTH Receptor Signaling 
2.1 Introduction 
Recent studies revealed altered modes of cAMP signaling for GPCRs where transient cAMP 
responses originate from cell membrane receptors, whereas internalized receptors prolong cAMP 
production from intracellular membranes [31, 53-55].  Initially uncovered for the PTHR, a class B 
GPCR that primarily couples of Gs/cAMP and Gq/Ca
2+ signaling pathways and plays a central role 
in regulating Ca2+ homeostasis and bone turnover, this model is considered a new paradigm for 
GPCR signaling that can be viewed as a new form of signaling bias as it relates to distinct location 
and duration of cAMP generation [55-57].  Parts of cellular mechanisms of this unexpected process 
have been determined for the PTHR [38, 41, 44, 58], but its structural determinants and relevance 
for human disease remain unknown.  Given that large fluctuations in extracellular Ca2+ observed 
in bone can reach up to 40 mM due to dynamic bone remodeling processes [59] and the reported 
effect of Ca2+ on PTH binding to purified receptor [60], we questioned whether changes in local 
extracellular Ca2+ concentrations could affect PTHR signaling in live cells.  Here, we show through 
a series of biochemical and cell biological approaches that extracellular Ca2+ binds to the first 
extracellular loop of the receptor and acts as a positive allosteric modulator of PTHR signaling by 
increasing ligand residence time on the receptor and amplifying sustained cAMP production.  We 
also show that the sensitivity to Ca2+ is lost for the recently identified homozygous PTH variant 
(R25C), implicated as a novel cause of chronic hypocalcemia in humans [52].   
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2.2 Materials and Methods 
2.2.1 Cell Culture and Transfection 
Cell culture reagents were obtained from Corning (CellGro).  Human embryonic kidney 
cells (HEK293; ATCC, Georgetown, DC) stably expressing the recombinant human PTHR were 
grown in selection medium (DMEM, 5% FBS, 1% penicillin/streptomycin, 500 µg/mL neomycin) 
at 37 °C in a humidified atmosphere containing 5% CO2.  Primary mouse calvarial osteoblast (Ob) 
cells were isolated and cultured as described [58].  Human renal proximal tubule epithelial cells 
(RPTEC) were grown in DMEM/F12 supplemented with 5 pM triiodo-L-thyronine, 10 ng/mL 
recombinant human epidermal growth factor, 25 ng/mL prostaglandin E1, 3.5 µg/mL ascorbic acid, 
1 mg/mL insulin, 0.55 mg/mL transferrin, 0.5 µg/mL sodium selenite, 25 ng/mL hydrocortisone, 
and 1% penicillin/streptomycin.  For transient transfection, cells were seeded on glass coverslips 
coated with poly-D-lysine in six-well plates and cultured for 24 hours prior to transfection with 
the appropriate cDNAs using Fugene-6 (Promega) or Lipofectamine 3000 (Life Technologies) for 
48-72 hours before experiments.  We optimized expression conditions to ensure expression of 
fluorescently labeled proteins was similar in examined cells by performing experiments in cells 
displaying comparable fluorescence levels.   
2.2.2 Assessment of Receptor Cell Surface Expression by FACS 
HEK293 cells were grown on 10 cm tissue culture plates and transfected with HA-tagged 
wild-type or ECL1 mutant PTHR constructs, as described above, using equal amounts of plasmid 
DNA for each construct.  After 48 hours, the plates with cells were placed on ice, and cells were 
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washed with cold phosphate-buffered saline (PBS) (Lonza, #17517Q).  Cells were detached by 
applying PBS supplemented with 0.5 mM EDTA, transferred to microcentrifuge tubes and spun 
down at 100xg for 2 min.  Cell pellets were washed with blocking buffer (PBS with 0.5% BSA 
and 0.5% FBS), then resuspended in 0.75 mL blocking buffer with mouse anti-HA antibody 
(BioLegend, #901513) at 1:1000 dilution and incubated for 1 hour at 4 °C.  After two washes with 
blocking buffer, cells were resuspended in blocking buffer with anti-mouse Alexa Fluor 568 
antibody (Abcam, #ab175473) at 1:300 dilution and incubated for 1 hour at 4 °C.  Cells were 
washed with blocking buffer and resuspended in 0.25 mL of blocking buffer for FACS 
measurements.  FACS analysis was performed on BD FACSCalibur instrument and CellQuestPro 
software (BD Biosciences) taking 100,000 cells per analysis.   
2.2.3 Peptides, Chemicals, Mutagenesis, and Western Blot Analysis 
PTH(1-34), PTH(1-34)R25C, PTH(1-34)R25S, PTH(1-34)R25A, PTH(1-34)TMR, PTH(1-
34)R25CTMR, and [M]-PTH(1-14) (M=BVBEIQLOHQZAKWY-NH2, where B = aminoisobutyric 
acid; O = norleucine, Z = homoarginine) were synthesized and characterized as previously 
described [44].  Abaloparatide (#H-8334) was purchased from Bachem.  Dynasore (#324410) and 
forskolin (#344270) were purchased from EMD-Millipore.   
 Receptor mutagenesis converting 251DEAE254→SSAS (ECL1-1) and 257EEE259→SSS 
(ECL1-2) were performed using the QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies, #200523) using the provided protocol and the following primers:  
GGCGCCACGCTTTCTTCTGCTTCGCGCCTCACCGAGG for ECL1-1, and 
GCTGAGCGCCTCACCTCTTCTTCTCTGCGCGCCATCG for ECL1-2, and their 
corresponding reverse complement primers. 
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 For Western blot analysis, total protein extracts were prepared using cell lysis buffer (1% 
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 7.4, 100 mM NaCl, 2 mM EDTA, 
50 mM NaF) containing EDTA-free Protease Inhibitor Cocktail (Roche Diagnostic GmbH).  
Protein concentrations were quantified by the Micro BCA protein assay kit (ThermoFisher 
scientific #23225) according to the manufacturer’s instructions.  Equal amounts of protein were 
separated by SDS-PAGE (10% SDS) and transferred to a nitrocellulose membrane.  Membranes 
were blocked for 1 hour in TBS containing 5% non-fat milk, 1% BSA, and 0.1% Tween20, then 
incubated overnight with mouse anti-HA antibody (Covance).  Membranes were then incubated 
with HRP-conjugated polyclonal goat anti-mouse antibody (Dako).  The same membranes were 
subsequently stripped for 5 minutes at room temperature in Western blot stripping buffer (10% 
SDS, 0.5 M Tris pH 6.8, 0.8% β-mercaptoethanol), and then reprobed with mouse anti-βactin 
antibody (Cell signaling) and HRP-conjugated secondary antibody. 
2.2.4 Saturation Binding at Equilibrium 
Stably or transiently transfected HEK293 cells grown in 96-well plates were incubated in 
Hepes buffer (137 mM NaCl/5 mM KCl/1 mM MgCl2/20 mM HEPES, pH 7.4) for 1 hour at 4 °C, 
followed by 17 hour incubation at 4 °C in the presence of increasing concentrations of TMR-
labeled PTH or PTHR25C and distinct [Ca2+] as indicated in figures.  Cells were washed twice with 
the same buffer, and fluorescence intensities were recorded at 580 ± 20 nm using an excitation 
wavelength of 525 ± 20 nm on a Tecan Spark 20M multimode microplate reader.  Non-specific 
binding was determined using 1 µM of unlabeled ligand.  Data were subsequently analyzed using 
GraphPad Prism 7.0 (GraphPad Software Inc., La Jolla, CA).  
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2.2.5 Laser Scanning Confocal Microscopy 
Cells plated on coverslips were mounted in Attofluor cell chambers (Life Technologies) 
and incubated with HEPES buffer (150 mM NaCl, 20 mM HEPES, 2.5 mM KCl, varied [Ca2+], 
0.1% BSA, pH 7.4) and transferred on the Nikon Ti-E microscope (Nikon) equipped with a Z-
driven piezo motor.  Imaging was performed using Nikon A1 confocal unit, through a 60X N.A. 
= 1.45 objective (Nikon).  Fluorescent antibody (anti-HA-Alex488, Cell Signaling, #2350), 
proteins or peptides containing CFP, Turqoise, GFP, FITC, YFP, tetramethylrhodamine (TMR) 
were excited with 440 nm (CFP, Turquoise), 488 nm (Alexa488, GFP, FITC), 514 nm (YFP) or 
561 nm (TMR) lasers (Melles Griot).  Data acquisitions were done using Nikon Element Software 
(Nikon Corporation).  After acquisition, raw data were analyzed using ImageJ software.  Each 
different analysis was done at the single-cell level. 
2.2.6 Time-course Measurements of cAMP Production in Live Cells 
cAMP was assessed using FRET-based assays.  Cells were transiently transfected with the 
FRET-based biosensor Epac1CFP/YFP [61] for measuring cAMP.  Measurements were performed 
and analyzed as previously described [62].  In brief, cells plated on poly-D-lysine coated glass 
coverslips were mounted in Atoofluor cell chambers (Life Technologies), maintained in a HEPES 
buffer containing 150 mM NaCl, 20 mM HEPES, 2.5 mM KCl, 0.1-10 mM CaCl2, 0.1% BSA, 
and pH 7.4 and transferred on the Nikon Ti-E equipped with an oil immersion 40X numerical 
aperture 1.30 Plan Apo objective and a moving stage (Nikon Corporation).  CFP and YFP were 
excited using a mercury lamp.  Fluorescence emissions were filtered using a 480 ± 20 nm (CFP) 
and 535 ± 15 nm (YFP) filter set and collected simultaneously with a LUCAS electron-multiplying 
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charge-coupled device camera (Andor Technology) using a DualView 2 (Photometrics) with a 
beam splitter dichroic long pass of 505 nm.  Fluorescence data were extracted from a single cell 
using Nikon Element Software (Nikon Corporation).  The FRET ratio for single cells was 
calculated and corrected as previously described [63].  Individual cells were perfused with buffer 
or with ligand for the time indicated by the horizontal bar.   
2.2.7 Receptor Recycling 
Live-image trafficking of SEP-PTHR was done as described [64] using a Nikon A1 
confocal microscope.  Briefly, HEK293 cells stably expressing a pH-sensitive GFP variant, 
superecliptic pHluorin, inserted in the N-terminal domain of the human PTHR (SEP-PTHR) were 
seeded onto glass coverslips coated with poly-D-lysine (Sigma #P7280) for 24 hours.  Experiments 
were carried out at 37 °C in FRET buffer used for cAMP experiments.  Cells were stimulated by 
the ligand for 10 minutes then washed out to allow recycling.  Images were acquired every 30 
seconds. 
2.2.8 Endosomal pH 
Estimates were made using FITC fluorescence data together with the pH standard plot as 
previously described [44]. 
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2.2.9 Purification of PTHR 
Human PTHR construct comprising amino acid residues 27-483, with HA signal peptide 
for cell surface expression and with residues 58-106 replaced by GSGS linker, carrying N-terminal 
Flag tag and C-terminal 8x His tag was cloned into pFastBac1 vector.  The baculovirus was 
generated according to procedures provided by Bac-to-Bac Expression Systems (Thermfisher).  
The receptor was expressed in Sf9 insect cells, grown in protein-free insect cell media ESF-921 
(Expression Systems, #96-001-01) supplemented with penicillin/streptomycin.  Cells were 
infected when density reached 5x106/mL with 60X dilution of P2 baculovirus and cultured at 27 
°C for 50 hours.  Cells were harvested by centrifugation and stored at -80 °C until used.  Cells 
were lysed by dounce-homogenization in lysis buffer consisting of 50 mM Tris-HCl pH 8.0, 100 
µM TCEP, and protease inhibitors.  To the lysate, 0.3% DDM, 0.3% DMNG, 0.06% CHS, 30 mM 
imidazole, 0.4 M NaCl, and 8% glycerol were added, and receptor extraction was carried out for 
1 hour at 4 °C.  After clearing the extract by centrifugation at 29,000xg for 30 min, the PTHR was 
captured onto Ni 6 Fast Flow sepharose (GE Healthcare, #17531801) by batch-binding for 2 hours 
at 4 °C.  The beads were washed with Ni buffer consisting of 20 mM HEPES pH 7.5, 0.4 M NaCl, 
30 mM imidazole, 2% glycerol, 0.008% DMNG, 0.0008% CHS, 100 µM TCEP, and protease 
inhibitors, then eluted with Ni buffer supplemented with 0.4 M imidazole and 4 mM CaCl2.  Ni 
eluate was incubated with anti-Flag-M1 agarose (Sigma-Aldrich, #4596) for 1 hour at 4 °C, 
washed with buffer consisting of 20 mM HEPES pH 7.5, 150 mM NaCl, 4 mM CaCl2, 1% glycerol, 
0.008% DMNG, 0.0008% CHS, then eluted with 20 mM HEPES pH 7.5, 150 mM NaCl, 10 mM 
EDTA, 0.1 mg/mL Flag peptide, 1% glycerol, and 0.008% DMNG.  The eluted receptor was 
concentrated using Amicon Ultra-15 50 kDa MWCO spin-concentrators (Millipore-Sigma, 
#UFC905008) to 1 mL, and then injected to Superose 6 10/300 GL (GE Healthcare) gel-filtration 
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column equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 0.008% DMNG, and 0.0008% 
CHS.  The yield of purified receptor was 0.2-0.5 mg from 1 L insect cell culture. 
2.2.10 Assessment of Purified Receptor Functionality 
The functionality of purified receptor was tested in terms of its ability to form complex 
with Gs protein.  To this end, the PTHR was incubated with 2-3 fold molar excess of LA-PTH, Gs 
heterotrimer, and nanobodies Nb35 and Nb37GFP for 40 minutes at room temperature.  Then 2 µL 
of apyrase (NEB, #M0398S) was added, and the reaction mixture was incubated at room 
temperature for 40 minutes.  The formed complex was captured onto anti-Flag-M1 agarose beads 
packed in an Econo column, washed, and eluted using the same buffers as for receptor purification, 
but supplemented with 50 nM LA-PTH.  The eluted sample was concentrated using Amicon Ultra-
4 100 kDa MWCO spin-concentrators (Millipore-Sigma, #UFC810008) to 1 mL, then injected to 
Superose 6 10/300 GL gel-filtration column equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 
0.008% DMNG, and 0.0008% CHS.  The constructs of Gs heterotrimer and Nb35 were provided 
by Dr. Cheng Zhang (University of Pittsburgh) and purified as described previously [65].  The 
Nb37GFP construct was a kind gift from Dr. Mark zon Zastrow (UCSF).  The 10xHis tag was 
inserted at the C-terminus of GFP and the construct was subcloned to pEt21a.  The Nb37GFP was 
expressed in Shuffle T7 Express Competent E. coli strain (NEB #C3029J) that is engineered to aid 
correct disulfide folding of target proteins in the cytoplasm.  The cells were cultured at 37 °C in 
LB media supplemented with ampicillin.  When cell density reached OD600 0.75, the temperature 
was lowered to 18 °C and protein expression was induced with 0.4 mM IPTG.  After induction, 
the cells were grown for 20 hours at 18 °C, and then harvested by centrifugation and resuspended 
in buffer consisting of 50 mM Tris-HCl pH 8.0, 0.4 M NaCl, 30 mM imidazole, and protease 
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inhibitors.  Cells were lysed by sonication, then spun down 50,000xg for 25 minutes to clear the 
lysate.  The Nb37GFP was captured onto Ni 6 Fast Flow sepharose beads by batch-binding for 1.5 
hours at 4 °C.  Beads were excessively washed with Ni buffer (25 mM Tris-HCl pH 8.0, 0.4 M 
NaCl, 30 mM imidazole, and protease inhibitors), then eluted with Ni buffer supplemented with 
0.4 M imidazole.  Ni eluate was concentrated using Amicon Ultra-15 30 kDa MWCO spin-
concentrators (Millipore-Sigma, #UFC903008) to 1 mL, then injected to Superose 6 10/300 GL 
gel-filtration column equilibrated in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, and protease 
inhibitors.  The purified protein was aliquoted, flash-frozen, and stored at -80 °C until used. 
2.2.11 Homology Modeling of PTHR 
To model PTH binding to PTHR, we generated a homology model of PTHR via GPCR-I-
TASSER [66].  We first aligned the N-PTHR/PTH(15-34) crystal structure (PDB 3C4M) [67] with 
the ECD of the highest scoring PTHR model.  Next, we aligned the crystal structure of PTH(1-34) 
alone (PDB 1ET1) [68] with PTH(15-34) from N-PTHR/PTH(15-34).  Backbone-dependent 
conformers of R25 were assessed, revealing R25 could be oriented toward ECL1, and figures were 
generated in PyMOL (Molecular Graphics System, Version 2.0 Schrӧdinger, LLC).   
2.2.12 Photometric FRET Recordings of Kinetics of Ligand Binding and Receptor 
Activation 
FRET experiments were performed as previously described [63].  In brief, cells grown on 
glass coverslips were maintained in buffer A (137 mM NaCl, 5 mM KCl, 1 mM MgCl2, 20 mM 
HEPES, pH 7.4) at room temperature and placed on a Zeiss inverted microscope (Axiovert 200) 
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equipped with an oil immersion X100 objective and a dual emission photometric system (TILL 
Photonics, Germany).  Cells were excited with light from a polychrome V (TILL Photonics).  To 
minimize photobleaching, the illumination time was set to 5-15 ms applied with a frequency 
between 1 and 75 Hz.  For binding events, the illumination time was typically set to 5 ms applied 
with a frequency of 40 Hz.  FRET was monitored as the decrease in emission of GFP (FGFP) from 
the PTHR N-terminally tagged with GFP (PTHR-GFP) in the presence of TMR-labeled peptides, 
recorded at 520 ± 20 nm (beam splitter 530 DCLP) upon excitation at 480 ± 20 nm (beam splitter 
498 DLCP).  Because the diminution of GFP fluorescence was due to FRET between GFP and 
TMR [69], we used the decline of GFP fluorescence as readout for the binding event.  The spillover 
of TMR into the 520 nm channel (1.5%) was negligible.  For receptor activation, the emission 
fluorescence intensities were determined at 535 ± 15 and 480 ± 20 nm (beam splitter dichroic long-
lass (DCLP) 505 nm) upon excitation at 436 ± 10 nm (DCLP 460 nm) and were corrected for the 
spillover of CFP into the 535 nm channel, the spillover of YFP into the 480 nm channel, and the 
direct YFP excitation to give a corrected FRET emission ratio FYFP/FCFP.  Changes in fluorescence 
emissions due to photobleaching were systematically subtracted.  To determine agonist-induced 
changes in FRET, cells were continuously superfused with the buffer A with a range of CaCl2 
concentrations and agonist was applied using a computer-assisted solenoid valve-controlled rapid 
superfusion device ALA-VM8 (ALA Scientific Instruments) (solution exchange 5-10 ms).  Signals 
detected by avalanche photodiodes were digitized using a converter (Digidata1322A; Axon 
Instruments) and stored on PC computer using Clampex 9.0 software (Axon Instruments).  Data 
were analyzed using the program Origin (OriginLab Corp.).   
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2.2.13 Detection of Ca2+ Binding PTHR Fragments by Liquid Chromatography with 
Tandem Mass Spectrometry 
For non-SILAC experiments, HEK293S cells stably expressing HA-tagged PTHR (HA-
PTHR) were grown in regular DMEM supplemented with 5% FBS and 1% 
penicillin/streptomycin.  For SILAC experiments, HEK293S cells stably expressing HA-PTHR 
were grown in SILAC DMEM.  The SILAC medium was prepared from custom-ordered DMEM 
powder without arginine and lysin (ThermoFisher #88425).  L-lysine-[13C6,
15N2] (50 mg/L) and 
L-arginine-[13C6, 
15N4] (25 mg/L) were added to the “heavy” medium, whereas equal concentration 
of conventional L-lysine-[12C6, 
14N2] and L-arginine-[
12C6, 
14N4] were added to the “light” 
medium.  Cells were maintained in heavy and light SILAC media side-by-side for at least 7 
doubling until the isotope incorporation efficiency achieved >95% as determined by mass 
spectrometry.  The cells were then grown to ~80% confluence.  The heavy cells were stimulated 
with 100 nM PTH for 15 minutes before harvesting, and the light cells werved as control without 
any treatment.  After treatment, equal numbers of heavy and light cells were mixed and served as 
SILAC cell samples.  Non-SILAC and SILAC cell samples were lysed in buffer containing 50 mM 
HEPES pH 7.5, 0.5% NP-40, 250 mM NaCl, 10% (v/v) glycerol.  The HA-PTHR was isolated 
from cell lysates using anti-HA agarose beads.  Purified HA-PTHR samples were digested by 
trypsin using an in-solution trypsin digestion protocol was described previously [70].  For in vitro 
Ca2+ binding experiments, PTHR was purified from Sf9 cells was described above and diluted to 
0.1 µg/µL in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% DDM.  The purified PTHR was then 
incubated with or without 1 mM CaCl2 at room temperature for 30 minutes before subjection to 
in-solution trypsin digestion.  After peptide desalting with in-house prepared stage-tip, tryptic 
peptides were reconstituted in a solution containing 0.1% formic acid and 2% acetonitrile and 
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analyzed on a nanoACQUITY (Waters)-LTQ Orbitrap Velos mass spectrometer (Thermofisher) 
system.  The LTQ Orbitrap Velos was operated in the data dependent mode using the TOP10 
strategy.  In brief, each scan cycle was initiated with a full MS scan of high mass accuracy 375-
1,800 m/z, acquired in the Orbitrap at 6x104 resolution setting and automatic gain control (AGC) 
target of 106, which was followed by MS/MS scans (AGC target 5,000; threshold 3,000) in the 
linear ion trap on the ten most abundant precursor ions.  Selected ions were dynamically excluded 
for 30 seconds.  MS data analysis was performed using SEQUEST software against Uniprot Homo 
sapiens forward and reverse protein sequences.  To search for evidence of Ca2+ containing 
peptides, each LC-MS/MS data set was manually examined to look for additional MS peaks 
matching exactly the possible theoretical m/z change (Δm/z = 37.946941, z = 1; Δm/z = 18.97347, 
z = 2; Δm/z = 12.64898, z = 3) when a single Ca2+ ion binds to the PTHR.  For SILAC data, the 
m/z differences between the light and heavy version of free peptides and Ca2+ binding peptides 
were examined to ensure they matched. 
2.2.14 Statistical Analysis 
Data were processed using Excel 2013 (Microsoft Corp. Redmond, WA) and Prism 7.0 
(GraphPad Software Inc., La Jolla, CA).  Data are expressed as mean ± SEM.  Curves were fit to 
the data using a four-parameter, non-linear regression function.  Statistical analyses were 
performed using unpaired, 2-tailed Student’s t tests for comparisons between 2 groups. 
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2.3 Results 
2.3.1 Extracellular Ca2+ Prolongs Ligand Residence Time and Promotes Receptor 
Activation and Endosomal cAMP Production 
Both in human and embryonic kidney 293 (HEK293) cells and primary osteoblasts 
expressing recombinant and native PTHR, respectively, we observed a significant (P < 0.01) 
difference in magnitude and duration of cAMP production when a range of Ca2+ concentrations 
(0.1-10 mM) were co-applied with PTH (Fig. 1A,C).  The effective concentration that gives half 
maximal response (EC50) for PTH-induced cAMP decreased 30-fold when the Ca
2+ concentration 
was increased from 0.1 to 10 mM (Fig. 1B, left).  Ca2+ had no effect by itself but caused a 
concentration-dependent increase in PTH-mediated cAMP response with an EC50 value (1.01 mM) 
near the physiological range of ionized serum Ca2+ levels (1.1-1.3 mM) (Fig. 1B, right).  These 
data show that Ca2+ significantly enhances both the magnitude and the duration of PTH-induced 
cAMP generation.  Surprisingly, potentiation of PTHR signaling was ligand-dependent, as PTHrP-
induced cAMP lacked sensitivity to Ca2+ (Fig. 1D), whereas its analog ABL, recently Food and 
Drug Administration approved to treat osteoporosis, showed sensitivity similar to that of PTH 
(Fig. 2A).  We thus utilized either PTH or ABL as ligand in subsequent experiments.  
To further interrogate the mechanism by which extracellular Ca2+ regulates receptor 
signaling, effects on ligand binding were assessed via equilibrium and kinetic analyses.  Saturation 
binding experiments using tetramethylrhodamine (TMR)-labeled PTH (PTHTMR) revealed 
moderate increases in ligand binding affinity in the presence of increasing extracellular Ca2+, a 
defining characteristic of a positive allosteric modulator (Fig. 1E).  In an effort to confirm that 
Ca2+-mediated effects on ligand binding are responsible for the observed modulation of cAMP  
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Figure 1. Allosteric Action of Extracellular Ca2+ on PTH Signaling. 
(A) Averaged cAMP responses over 35 min in HEK293 cells stably expressing the PTHR stimulated with 10 pM, 1 
nM, and 10 nM PTH in the presence of a range of [Ca2+]. (B) cAMP responses for experiments represented in A, 
determined by measuring the area under the curve (a.u.c) from 0 to 35 min (left).  The effect of increasing 
concentration of Ca2+ on PTH (10 nM)-mediated cAMP (right). (C) Averaged time courses of cAMP production rat 
primary osteoblasts upon stimulation with 100 nM rat PTH (rPTH) in the presence of increasing Ca2+ concentrations. 
(D) PTHrP-induced cAMP responses are insensitive to Ca2+ modulation. (E) Saturation binding isotherms of PTHTMR 
to the PTHR stably expressed in HEK293 cells with a range of [Ca2+]. (F) Averaged time-courses of venus-tagged 
mini Gs (mGsvenus) recruitment to PTHRCFP in response to PTH in the presence of a range of extracellular [Ca2+] 
measured by FRET in HEK293 cells.  Data represent the mean ± SEM of N=3 experiments carried out in triplicate 
for E and n = 8-30 cells/experiments for other panels. 
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Figure 2. Ligand Residence Time Determined by Ca2+ Allostery. 
(A) Averaged cAMP response over 35 minutes in HEK293 cells stably expressing the PTHR stimulated with 10 nM 
and 10 pM ABL in the presence of a range of [Ca2+]. (B) Time courses of ABLTMR binding to PTHRGFP expressed in 
HEK293 cells.  Measurements were recorded in single cells continuously perfused with buffer or 1 µM ABLTMR 
(horizontal bar) in the presence of varying [Ca2+]. (C) Comparison of ligand dissociation time courses from 
experiments in B (left) and the corresponding residence time of the ligand, calculated as the inverse of the rate constant 
of ligand dissociation (1/koff) as a function of [Ca2+] (right). (D and E) Effects of Ca2+ on time courses of receptor 
activation/deactivation using PTHRCFP/YFP stably expressed in HEK293 cells.  Single cells were continuously perfused 
with buffer or 1 µM PTH (D) or ABL (E, left) indicated by the horizontal bar.  Time constants (τoff) of receptor 
deactivation (E, right) as a function of [Ca2+] calculated from experiments similar to E (left).  Data represent the mean 
± SEM of N=3 experiments and n=8-30 cells/experiment. 
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responses, Gs recruitment to the receptor was measured by Fӧrster Resonance Energy Transfer 
(FRET) using mini-Gs
venus and CFP-tagged PTHR (PTHRCFP).  Even at saturating concentration 
of ligand, increasing extracellular Ca2+ concentration resulted in enhanced recruitment of G protein 
with faster kinetics (Fig. 1F).  
Consistent with a positive allosteric action, increasing extracellular Ca2+ concentration also 
prolonged ligand residence time ((1/koff, where koff is the dissociation rate constant) following 
washout as measured by changes in FRET between TMR-labeled ABL (ABLTMR) and GFP fused 
N-terminally to PTHR (PTHRGFP) (Fig. 2B,C).  We reasoned that slower ligand dissociation 
kinetics should, in turn, impact the duration of receptor activation.  Accordingly, we utilized a 
previously characterized FRET-based conformational biosensor (PTHRCFP/YFP) to measure the 
time-course of receptor activation and deactivation by monitoring changes in the FRET ratio upon 
stimulation and washout, respectively.  We observed that increasing extracellular Ca2+ 
concentration resulted in an increased magnitude of PTHR activation by PTH and ABL, suggesting  
a key role in stabilizing the agonist-bound PTHR in an active conformation (Fig. 2D; E, left).  Ca2+ 
also caused a concentration-dependent increase in the deactivation time constant (τoff) after ABL 
washout (Fig. 2E, right), reflective of prolonged receptor activation.  Collectively, these results 
demonstrate that extracellular Ca2+ acts as a positive allosteric modulator of the PTHR by 
prolonging ligand residence time and receptor activation, which, in turn, significantly alters the 
magnitude and kinetics of the cAMP response. 
2.3.2 Mass Spectrometry Evidence of Ca2+ Binding to Extracellular Loop 1 of the Receptor 
We next sought to identify Ca2+ binding sites on the PTHR via liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS).  To this end, two populations of HEK293S 
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cells stably expressing HA-tagged PTHR (HA-PTHR) were cultured side-by-side in stable isotope 
labeling with amino acids in cell culture (SILAC) media containing either “light” (Lys-[12C6, 14N2] 
and Arg-[12C6, 
14N4]) or “heavy” (Lys-[13C6, 15N2] and Arg-[13C6, 15N4]) isotopic forms of amino 
acids.  The heavy cells were stimulated with 100 nM PTH(1-34) for 15 minutes, and the light cells 
served as control.  Upon mixing lysates from equal numbers of light and heavy cells, HA-PTHR 
was immunoprecipitated and enzymatically digested by trypsin and subjected to LC-MS/MS 
analysis using a high-resolution and mass accuracy linear trap quadrupole Orbitrap Velos mass 
spectrometer.  We identified MS peaks (charge state z = 2) corresponding to light and heavy 
version of the free peptides 241DAVLYSGATLDEAER255 (monoisotopic m/z = 805.39252 for 
light and m/z = 810.39624 for heavy) and 256LTEEELR262 (monoisotopic m/z = 445.23596 for 
light and m/z = 450.23998 for heavy) covering parts of the PTHR’s extracellular loop 1 (ECL1) 
(Fig. 3A).  Additional peaks matching exactly the theoretical mass-to-charge change (Δm/z) when 
a single Ca2+ ion binds to these peptides (Δm/z = 18.97347) were simultaneously detected for their 
corresponding light and heavy versions with monoisotopic m/z = 824.36597 (light) and 829.36926 
(heavy) for 241DAVLYSGATLDEAER255 and monoisotopic m/z = 464.20917 (light) and 
469.21348 (heavy) for 256LTEEELR262 (Fig. 3A).  Furthermore, the extent of Ca2+ binding was not 
significantly altered by PTH stimulation. 
 Given the well-known ability of acidic amino acid clusters to chelate Ca2+ and the presence 
of such clusters in each of the peptides identified by MS, we then generated two PTHR mutants 
wherein negatively charged aspartates (D) or glutamates (E) were substituted with serine (S) side 
chains to impair Ca2+ chelation without significant impact on overall polarity:  251DEAE254→SSAS 
(noted ECL1-1), and 257EEE259→SSS (noted ECL1-2).  Interestingly, both ECL1 mutants were 
unable to engage in sustained cAMP production was efficiently as the wild-type (WT) receptor  
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Figure 3. Involvement of the Receptor’s ECL1 in Ca2+ Allostery. 
(A) Representative MS of the tryptic digest of the PTHR from SILAC experiments showing the identified peptide 
256LTEEELR262 located within the ECL1 of the receptor.  The free and Ca2+-bound versions of the peptide were 
detected simultaneously.  The red and blue colors represent light and heavy versions of the peptide.  The theoretical 
mass-to-charge differences (Δm/z) between free and Ca2+-bound peptides are shown for both light and heavy versions.  
The Δm/z values of the corresponding light and heavy peptides are 5.  For clarity, the MS peaks for Ca2+-bound 
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peptides are enlarged and highlighted in a gray box. (B) Averaged time courses of cAMP production in response to 
PTH in HEK293 cells expressing wild-type (WT) PTHR or PTHR-ECL1 mutants measured by FRET in response to 
10 nM PTH. (C) Averaged dissociation time courses of PTHTMR from GFP-tagged PTHR WT (black), ECL1-1 (red), 
or ECL1-2 (blue).  FRET recordings from HEK293 cells are shown as a normalized ratio. (D) The effect of 0.1 and 
10 mM Ca2+ on cAMP response mediated by 10 nM PTH in HEK293 cells expressing PTHR WT or ECL1 mutants.  
cAMP responses were quantified by measuring the area under the curve from 0 to 35 minutes and are represented as 
percentage differences from the 1 mM Ca2+ condition. (E) Saturation binding isotherms of PTHTMR to ECL1 mutants 
stably expressed in HEK293 cells.  The mean ± SEM of N=3 experiments carried out in triplicate. (F) The bars 
represent the mean of the KD values ± SEM of binding experiments shown in 1C and 3E. *Significantly different when 
P < 0.05.  cAMP time courses represent the mean value ± SEM of N=3 with n=14-26 cells/experiment. 
 
(Fig. 3B).  Despite normal internalization, PTH dissociated with markedly faster kinetics from 
receptor mutants compared with WT receptor, consistent with more transient cAMP responses 
(Fig. 3C).  Time courses of cAMP measurements for ECL1-1 and ECL1-2 receptor mutants in 
response to PTH revealed markedly reduced sensitivity to Ca2+, particularly for ECL1-2 (Fig. 3D).  
Similarly, receptor mutants failed to mimic the effects of Ca2+ concentration on ligand binding that 
were observed for WT receptor in saturation binding experiments (Fig. 3E,F).  These results 
suggest that acidic residues within ECL1 of the PTHR serve as key determinants for mediating 
Ca2+ allostery and endosomal signaling by PTH. 
2.3.3 Positive Ca2+ Allostery is Lost for a Hypocalcemia-causing PTH Mutant 
Although negatively-charged amino acids within ECL1 of the PTHR clearly play a role in 
mediating allosteric modulation by Ca2+, the lack of sensitivity to Ca2+ concentration observed in 
PTHrP-induced cAMP responses suggests an additional ligand-dependent component.  We next 
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examined PTHR25C, a recently identified homozygous PTH variant wherein arginine (R) at position 
25 has been substituted with cysteine (C).  Patients harboring this mutation present with severe 
hypocalcemia despite normal or even excess levels of the circulating hormone, likely due to the 
reduced efficacy of PTHR25C in stimulating cAMP production [52], but the molecular basis for 
impaired signaling remains poorly understood.  Given the apparent correlation between PTHR 
sensitivity to Ca2+ concentration and the ability to promote normal cAMP responses, we 
questioned whether position 25 of PTH plays a role in mediating Ca2+ allostery and thus endosomal 
signaling.  Indeed, saturation binding analysis and cAMP time-course experiments in HEK293 
cells revealed that PTHR25C completely lacks sensitivity to extracellular Ca2+ concentration (Fig. 
4A,B).  Moreover, PTHR25C-induced cAMP generation was markedly shorter in duration than that 
of WT hormone (Fig. 4B).  Preventing PTHR internalization by expressing DynK44A had only 
minimal effect on cAMP induced by PTHR25C (Fig. 4C), suggesting that this signaling is mainly 
restricted to the cell surface.  Surprisingly, the inability of PTHR25C to sustain cAMP was not due 
to defective internalization and trafficking of ligand-bound PTHR into endosomes, as revealed by 
similar Pearson’s correlation coefficients between TMR-labeled ligands and either PTHR detected 
with anti-HA Alexa488 conjugated antibody or Rab5 labeled with GFP (Rab5-GFP) (Fig. 4D).  
We considered the possibility that R25 of PTH engages in ionic interactions with the negatively 
charged residues within ECL1 of PTHR because the reduced Ca2+ allostery and endosomal 
signaling observed with PTHR25C were mimicked by ECL receptor mutants (Fig. 4E).  The R25 
interaction with acidic residues within ECL1 is, indeed, supported by our homology model of the 
PTHR built to investigate possible structural interactions between PTH and ECL1 of the receptor 
(Fig. 4F).  In this model, R25 faces the acidic regions of ECL1 of the PTHR at a distance 
compatible with salt bridge formation.  The lack of R25 interaction with ECL1 acidic residues  
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Figure 4. Involvement of R25 of PTH in Interaction Stabilization and Receptor Signaling. 
(A) Saturation binding isotherms of TMR-labeled PTHR25C to PTHR stably expressed in HEK293 cells with [Ca2+] = 
0.1 (blue), 1 (black), or 10 (red) mM.  The mean ± SEM of N=3 experiments carried out in triplicate. (B) Averaged 
time courses of cAMP production in response to PTHR25C in HEK293 cells expressing the PTHR in the presence of a 
range of [Ca2+] measured by FRET. (C) Time courses of cAMP production in response to PTH (right) or PTHR25C 
(left) in HEK293 cells expressing the PTHR.  Experiments were run in two conditions:  cells expressing only the 
PTHR (black), and cells co-expressing the PTHR and DynK44A (gray). (D) Pearson’s correlation values obtained 
from colocalization experiments between TMR-labeled PTH or PTHR25C with anti-HA Alexa488 (HA-PTHR, right) 
or the early endosome marker Rab5GFP (left).  The arrows indicate the time of ligand stimulation. (E) Averaged time 
courses of cAMP production in response to PTHR25C in HEK293 cells expressing WT PTHR or ECL1 mutants (left), 
and dissociation time courses of TMR-labeled PTHR25C from WT or mutant PTHRGFP expressed in HEK293 cells 
(right) measured by FRET. (F) Homology model of the PTHR generated from GPCR-I-TASSER with the modeled 
PTH.  The PTHR is shown as an electrostatic surface, and PTH is represented as a green helix.  R25 of PTH points 
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toward an acidic face of the PTHR, which consists of ECL1-1 and ECL1-2 residues; R25 of PTH and residues of 
ECL1-1 and ECL1-2 are shown as sticks. (G) Time courses of internalization and recycling of PTHRSEP in response 
to ligand, measured by time-lapse confocal microscopy with images acquired every 30 seconds.  The baseline was 
established, and cells were stimulated with 100 nM ligand for 10 minutes then washed out. (H) Averaged dissociation 
time courses of TMR-labeled PTH or PTHR25C from PTHRGFP.  FRET recordings from HEK293 cells are shown as 
normalized ratios.  Cells were stimulated with 50 nM ligand for 30 seconds.  The gray line is a recording of pH using 
PTH-fluorescein isothiocyanate (FITC) in HEK293 cells expressing the PTHR C-terminally tagged with CFP.  Time 
courses represent the mean value ± SEM of N=3 experiments with n=8-20 cells/experiment. 
 
resulted in faster receptor recycling (Fig. 4G), likely due to faster dissociation of PTHR25C and 
increased pH sensitivity of this mutant hormone (Fig. 4H).  Collectively, these results provide 
strong evidence that ionic interactions between R25 of PTH and ECL1 residues of receptor are 
required for positive allosteric modulation by Ca2+ that likely stabilize hormone interaction with 
the receptor and thus are prerequisite for endosomal cAMP production. 
2.4 Discussion 
Over the past decades, it has been well-established that Na+ acts as a negative allosteric 
modulator of numerous class A GPCRs, wherein it binds to a conserved site within the seven 
transmembrane helix bundle and stabilizes an inactive state of the receptors [71].  In contrast, the 
divalent cations, such as Mg2+, Ca2+, and Mn2+, have been found to positively modulate class A 
GPCRs [72-77], and Ca2+ is a known allosteric regulator of several class C GPCRs [78].  Here, we 
reveal cellular and molecular mechanisms of positive allosteric actions of Ca2+ on a medically 
important class B GPCR, the PTHR. 
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 Indeed, PTH is an indispensable endocrine hormone regulating blood levels of Ca2+ and 
phosphate ions.  PTH binds to and activates its cognate receptor in bone, where it induces bone 
resorption that, in turn, releases ionized Ca2+ from the mineralized bone matrix.  Consequently, 
the receptor encounters elevated extracellular Ca2+ concentrations that can reach up to 40 mM [59].  
Here, we studied the effects of extracellular Ca2+ on PTHR ligand binding and signaling.  Our 
findings identify the ability of extracellular Ca2+ to act as an allosteric modulator of PTHR 
activation by promoting cAMP signaling when Ca2+ concentration is greater than 1 mM, and 
attenuating signaling when less than 1 mM.  We demonstrated that the sensitivity of PTHR 
signaling to Ca2+ allostery is dependent upon two acidic residue clusters in ECL1 of the receptor 
where possible Ca2+ coordination may promote interaction with ligands, and thus increasing their 
residence time on the receptor. 
 Our investigation of the cellular and molecular bases of hypocalcemia caused by a novel 
PTH variant where the arginine residue at position 25 is mutated to cysteine [52] revealed that this 
mutant has an impaired capacity to prolong cAMP responses from endosomes.  The mutant 
hormone’s conformation, binding affinity to the extracellular domain of the PTHR, and trafficking 
properties were comparable to WT PTH; however, we showed that mutation of R25 in PTHR25C 
renders this mutant insensitive to Ca2+ allostery and short-acting.  Our findings allow us to infer 
that R25 in PTH might be a key residue interacting with acidic clusters of receptor ECL1, and Ca2+ 
coordination at this site may further promote and stabilize this interaction.  We propose that Ca2+ 
allostery is a determinant of biased PTH agonism as it relates to the duration of PTHR signaling.  
Furthermore, the observed loss of sensitivity to Ca2+ in the disease-causing PTH variant unveils 
an unexpected role of Ca2+ in the etiology of hypocalcemia. 
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 Prolonged cAMP generation from endosomes was originally discovered for the PTHR 
[31], but its physiological relevance remained unknown until recently.  The first reliable link 
between endosomal cAMP responses and its physiological outcomes was provided by the finding 
that a long-acting PTH analog (LA-PTH), which triggers substantially longer endosomal cAMP 
responses than PTH, is also able to induce enhanced and prolonged blood Ca2+ elevation in mice 
and in monkeys compared with PTH [50, 79].  This link is further strengthened by this study 
demonstrating that the hypocalcemia-causing mutation in PTH displays defective endosomal 
PTHR signaling.  The opposing actions of PTH and PTHR25C as they relate to endosomal cAMP 
production in cells and calcemic responses in a human patient provide a better understanding of 
the disease relevance of endosomal PTHR signaling., which is likely the primarily signaling 
component of the PTH-mediated regulation of Ca2+ homeostasis in vertebrates. 
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3.0 Use of Backbone Modification to Enlarge the Spatiotemporal Diversity of Parathyroid 
Hormone Receptor-1 Signaling via Biased Agonism 
3.1 Introduction 
Information transfer at the molecular level is critical in living systems, and many natural 
messages are encoded in amino acid sequences.  Evolutionary modulation of these message is 
focused on side chains of proteins and peptides.  Chemical synthesis enables an expansion in 
polypeptide language via backbone modification, which can be implemented without change side 
chains.  We have begun to explore this approach in the context of polypeptide hormones that 
activate class B GPCRs, many of which are targets of therapeutic interest [80-83].  Previously, β-
amino acids have been used to modulate proteolytic stability, receptor-subtype selectivity, and 
signaling profiles of peptidic GPCR agonists [84-88].  The present study introduces a new 
capability of α→β substitution:  modulation of the spatiotemporal characteristics of signal 
transduction. 
 Agonist binding to a GPCR induces conformational changes that are sensed by cytosolic 
binding partners.  Different intracellular partners, such as Gs or βarrs, are predicted to engage 
distinct receptor conformations [89].  Biased agonism [90] is observed when a ligand favors a 
receptor conformation attractive to one partner relative to others.  Our group previously discovered 
that replacing multiple α-amino acid residues of glucagon-like peptide-1 (GLP-1) with cyclic β-
amino acid residues generated biased agonists favoring receptor interaction with βarrs relative to 
Gs.  However, these α/β-peptides were less potent agonists than the original α-peptide (GLP-1) 
[88].  Here, we show that minimal backbone alteration enabled by the use of homologous β-
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residues can generate potent agonists with high signaling selectivity at the PTHR and an altered 
spatiotemporal signaling profile relative to α-peptide prototypes. 
 The PTHR is an important target for the treatment of osteoporosis and hypoparathyroidism.  
Activation of the PTHR by its two native ligands, PTH and PTHrP, initiates Gs/cAMP/PKA 
signaling and βarr recruitment [91, 92].  PTH and PTHrP differ, however, in their spatiotemporal 
signaling profiles [93].  PTHrP causes transient cAMP production from receptors on the cell 
surface, while PTH triggers prolonged cAMP production after the receptor-agonist complex has 
translocated to endosomes [31, 44, 55]. 
 Signaling duration is an important determinant of the physiological effects exerted by 
PTHR agonists [36], but the subcellular location of GPCR signaling can also influence 
physiological outcomes [94].  Therefore, molecular tools that enable dissection of the spatial and 
temporal dimensions of PTHR signaling would be useful for elucidating the physiological roles of 
this receptor [45, 95].  We asked whether backbone modification could provide a PTHR agonist 
with a unique spatiotemporal signaling profile relative to natural hormones, specifically, an agonist 
that would induce prolonged receptor activation that occurs only at the cell surface.   
 Because binding of βarr to the PTHR is necessary for receptor internalization and 
attenuates cell-surface Gs/cAMP signaling [96], PTHR engaged by a Gs-biased agonist might 
persist at the cell surface and cause prolonged cAMP production from that location.  Previous 
approaches to Gs-biased agonists of the PTHR have involved amino acid side chain modification 
and achieved only limited success [92, 97, 98].  We pursued α→β backbone modification [84, 87, 
99, 100] with PTH(1-34) and with PTHrP analog abaloparatide (ABL), both of which are used to 
treat osteoporosis [101, 102]. 
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3.2 Materials and Methods 
3.2.1 Materials 
Fmoc-protected α-amino acids and O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HATU) were purchased from Chem-Impex 
International.  Fmoc-protected β3 amino acids were purchased from Chem-Impex International and 
PepTech Corporation.  Fmoc-protected β2 amino acids were synthesized by a previously reported 
method [103, 104] or using a modification of that method; details will be described elsewhere.  
NovaPEG Rink amide resin was purchased from Millipore Sigma.  The other reagents used for 
peptide synthesis and purification were purchased from Sigma-Aldrich.  For cell culture, 
Dulbecco’s Modified Eagle Medium (DMEM) and Fetal Bovine Serum (FBS) were purchased 
from Thermofisher Scientific.  For glosensor assays, the luciferase substrate (D-luciferin) was 
purchased from Goldbiotechnology. 
3.2.2 Peptide Synthesis, Purification, and Quantification 
Peptides were synthesized by microwave-assisted reactions on NovaPEG Rink amide 
resin.  For the coupling step, the resin was treated with 4 equivalents of protected amino acids, 4 
equivalents of HATU, and 8 equivalents of N,N-diisopropylethylamine (DIEA) in DMF.  The 
Fmoc deprotection was carried out by using 20% (v/v) piperidine with 0.1 M HOBT in DMF.  
Upon completion of the synthesis, peptides were cleaved from the resin using a solution of 94% 
trifluoroacetic acid (TFA), 2.5% H2O, 2.5% 1,2-ethanedithiol (EDT), and 1% triisopropylsilane 
(TIS).  After the cleave, the crude peptides were precipitated in cold diethyl ether and purified by 
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preparative HPLC.  Peptide purity was assessed by UPLC (BEH C18 stationary phase, 2.1 mm x 
100 mm, the solvent gradient is 10-60% acetonitrile over 5 minutes), and peptide mass was 
checked by MALDI-TOF MS.  All the peptides reported here were >90% pure as determined by 
UPLC.  Each α/β analogue of PTH(1-34) contains on tryptophan, and concentration was 
determined by UV spectroscopy using the absorbance at 280 nm.  For abaloparatide and its α/β 
analogues, there is neither tryptophan nor tyrosine in the sequence.  Concentrations in these cases 
were determined by UV spectroscopy using the absorbance at 214 nm [105].  After concentration 
determination, each peptide was aliquoted, lyophilized to dry powder, and stored at -20 °C.  For 
cell assays, each peptide was dissolved in 10 mM aqueous acetic acid to the final concentration of 
1 mM stock solution. 
3.2.3 Glosensor cAMP Assay 
HEK293 cells stably expressing the Glosensor cAMP reporter and human PTHR were 
cultured in DMEM supplemented with 10% FBS.  Cells were seeded into 96-well corning plates 
and used for cAMP assays after forming a confluent monolayer.  Upon the removal of culture 
medium, the intact cells in 96-well plates were incubated in CO2-independent medium containing 
D-luciferin (0.5 mM) for 20 minutes at room temperature.  After this period, cells in each well 
were treated with peptides at various concentrations, and luminescence resulting from cAMP 
production was measured for 30 minutes on a BioTek Synergy 2 plate reader.  The peak 
luminescence signaling (which usually appeared 14-20 minutes after peptide addition) were used 
to generate concentration-response curves.  The concentration-response curves were fit to the data 
by using the sigmoidal dose-response equation in Prism 6.0.  Reported EC50 and Emax values 
represent mean ± s.e.m of n ≥ 3 independent measurements. 
 39 
3.2.4 PTHR-βarr BRET Assay 
CHO-FlpIn cells transfected with PTHR-Rluc8 and βarr-1venus or βarr-2venus were cultured 
in DMEM supplemented with 10% FBS and 0.7 mg/mL hygromycin-B.  Cells were seeded into 
96-well plates at a density of 4x104 cells/well and cultured for 24 hours before the BRET assay.  
Cells were rinsed twice with DPBS to remove traces of phenol red and incubated in fresh DPBS 
containing coelenterazine-h (at a final concentration of 5 µM) at 37 °C for 10 minutes.  After this 
period, cells in each well were treated with peptides at various concentrations and BRET readings 
were collected for 25 minutes on a BioTek Synergy 2 plate reader with 460/40 and 528/20 nm 
emission filters.  The BRET signal was calculated by subtracting the ratio of 528/20 emission over 
460/40 emission for vehicle-treated cells from the same ratio for ligand-treated cells.  The peak 
BRET signals (which usually appeared within the initial 5 minutes after the peptide addition) were 
used to generate concentration-response curves.  The concentration-response curves were fit to the 
data by using sigmoidal dose-response equation in Prism 6.0.  Reported EC50 and Emax values 
represent mean ± s.e.m of n ≥ 3 independent experiments.  
3.2.5 Washout Assay 
For the washout experiments, cells preloaded with D-luciferin were treated with medium 
(vehicle) or agonists at the concentration of 1 nM for 14 minutes (ligand-on phase).  After this 
period, the medium in each well was removed and the cells were rinsed twice with CO2-
independent medium to remove unbound ligand.  After the addition of D-luciferin-containing fresh 
medium to each well, the luminescence was recorded for an additional 150 minutes (ligand-off 
phase).  For competitive antagonist-modified washout assays, the experimental protocol was as 
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described above except that the competitive antagonist (0.5 µM) was introduced during the ligand-
off phase.  For Bafilomycin A1 (BA1) and competitive antagonist-modified washout experiments, 
the cells were pretreated with medium containing 0.5 mM D-luciferin for 20 minutes in the 
presence or absence of 50 nM BA1.  After the ligand-on phase, as described above, the rinsed cells 
were incubated in D-luciferin-containing fresh medium with or without BA1 and competitive 
antagonist, and luminescence was monitored for 150 minutes. 
3.2.6 Co-immunoprecipitation 
HEK293 cells stably expressing HA-PTHR and cultured on a 10-cm dish were stimulated 
with PTH(1-34) or analogues at 100 nM at 5 minutes.  Cells were then washed with ice-cold PBS 
prior to cross-linking for 2 hours with DSP (Covachem, #13301) in PBS at 4 °C.  The reaction was 
stopped by addition of 10 mM Tris-HCl for 10 minutes and cell lysates were prepared using lysis 
buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.4, 140 mM NaCl, 0.5 mM EDTA) containing 
protease and phosphatase inhibitors (Roche, #11873580001).  Protein concentration was 
determined using BCA protein assay kit (ThermoFisher, #23225), and lysates were incubated with 
anti-HA agarose antibody beads (Sigma-Aldrich; #A2095 clone HA-7) overnight at 4 °C.  Elution 
was done using LDS loading buffer (Life Technologies) and samples loaded on 10% SDS-PAGE 
and transferred to nitrocellulose membrane.  We used antibodies against HA (Covance, clone 
16B12), and βarr-1/2 (Cell Signaling; #4674, clone D24H9).  Immunoreactive bands were 
visualized with Luminata Forte (EMD Millipore) and autoradiography film.   
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3.2.7 Hypothetical Molecular Basis for α/β Gs-biased PTHR Agonists 
Several structures of class B GPCRs bound to an agonist and Gs have been reported in 
recent years [106-109], but only one of these structures involves a biased agonist [106].  
Comparison of the GLP-1R TMD bound to GLP-1 versus a Gs-biased agonist peptide reveals 
several structural features that are potentially responsible for Gs-biased agonism of this receptor.  
The largest structural differences observed between these two ligand-bound GLP-1R TMDs 
involve TM helices 1, 6, and 7, as well as ECL3.  Due to the structural conservation among class 
B GPCRs, we speculate that conformational perturbations in these portions of other receptors may 
result in Gs-biased agonism in these cases as well. 
 We integrate the structural information for the GLP-1R discussed above with the recently 
solved structure of full-length PTHR bound to LA-PTH and Gs to formulate a hypothesis to explain 
the Gs bias displayed by our β-containing PTHR agonists.  Since the N-terminal portion of LA-
PTH largely corresponds to PTH(1-14), we hypothesize that PTH(1-34) is similar to LA-PTH in 
the manner in which the TMD of the PTH1R is engaged.  Backbone modification of PTH(1-34) at 
position 5, 7, or 8 results in significant signal bias.  In the PTHR structure, Leu7 of LA-PTH forms 
nonpolar contacts with TM1 and TM7 of the receptor, which seems consistent with “hot spot 
regions” proposed for Gs-biased agonism of GLP-1R [106].  Both Ile5 and Met8 of LA-PTH form 
nonpolar contacts with TM3 of PTHR, and the bottom of TM3 interfaces with the α5 helix of Gαs.  
Previous studies of the GLP-1R showed that a Gs-biased agonist of this receptor induced faster 
conformational change of Gs and greater efficacy of Gs-mediated cAMP signaling than did GLP-
1.  Such a functional distinction was suggested to arise because the biased agonist altered the 
positioning of the Gαs α5 helix by enhancing the conformational flexibility of the intracellular 
portion of the GLP-1R.  Thus, we speculate that the effect of backbone modification of PTH(1-
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34) at position 5 or 8 might propagate to Gs via TM3 of the PTHR, resulting in Gs-biased agonism 
upon backbone modification at either of these agonist positions. 
 The PTHR complex structure reveals that LA-PTH residue 1 forms hydrogen bonds with 
TM6 and ECL3 of the receptor.  These contacts could explain why side chain modification of 
residue 1 in PTH(1-34) scaffold can lead to Gs-biased agonism [98]. 
 We note that it is not possible to speculate about the effects of backbone modification in 
ABL scaffold at this time because no structural data are available.  ABL is a derivative of PTHrP(1-
34); these two peptides have the same N-terminal sequence, which differs from the N-terminal 
sequence of PTH(1-34).  Studies with PTH/PTHrP hybrid peptides reveal that the N-termini of 
PTH and PTHrP have very different affinities for the PTHR TMD [35, 110].  The different 
affinities may arise from distinct binding modes of PTH and PTHrP to the PTHR TMD. 
3.3 Results 
The N-terminal region of peptidic PTHR agonists inserts deeply into the transmembrane 
domain (TMD) and causes conformational changes to which transducers respond [109].  The 
PTHR conformation required for Gs activation appears to differ from that needed for recruitment 
of βarrs [111].  We hypothesized that backbone modification in the N-terminal region of PTH(1-
34) might induce PTH1R conformations that differentially affect Gs activation and βarr 
recruitment.  Our search for Gs-biased agonists based on PTH(1-34) began with a set of previously 
described analogues generated by replacing each of the first eight residues, individually, with the 
(S*)-β3, (S*)-β2, or (R*)-β2 homologue (Fig. 5; S* and R* defined in Fig. 5).  Several of these  
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Figure 5. α/β PTHR Agonists Displaying Significant Gs-biased Agonism Relative to PTH(1-34). 
β3 homoamino acids stereospecifically prepared from proteinogenic L-α amino acids are designated S*, based on the 
absolute configuration for (S)-β3-hAla.  S* and R* are applied to β2 residues as shown above, based on the absolute 
configurations of the two β2-hAla enantiomers.  nL denotes norleucine.  U denotes 2-aminoisobutyric acid. 
 
backbone-modified analogues (Fig. 6A) were indistinguishable from PTH(1-34) in stimulating 
cAMP production, as evaluated in HEK293 cells stably expressing human PTHR and the 
Glosensor for cAMP detection.  We evaluated these analogues for their ability to recruit βarrs to 
the receptor via bioluminescence resonance energy transfer (BRET) in CHO-FlpIn cells stably 
transfected with PTHRRluc8 and venus-tagged βarr-1 or βarr-2.  Considerable variation in 
recruitment of βarrs to the PTHR was observed, with incorporation of the (S*)-β2 homologue at 
position 5 or the (R*)-β2 homologue at position 7 or 8 (peptides 1-3) causing the most significant 
BRET reductions (Fig. 6A). 
With PTH(1-34) as the reference agonist, we quantified the signaling bias of peptides 1-3 
based on the Black-Leff operational model (Fig. 6C, 7), in which ΔΔlog(τ/KA) denotes the bias 
factor [112, 113].  This quantification method minimizesthe dependence of bias factor on cell type  
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Figure 6. Activity Profiles of PTH and α/β Gs-biased PTHR Agonists. 
(A,B) Concentration-response effects of PTH and peptides 1-6 for cAMP production and βarr-1 recruitment.  Data 
represent mean ± s.e.m from N≥6 independent experiments. (C) Calculated bias factors of 1-6 relative PTH(1-34). *, 
# Statistically significant difference from PTH using one-way ANOVA (* P < 0.0001; # P < 0.001). 
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Figure 7. Equations Used to Calculate Ligand Bias Factor. 
To quantify the relative capacity of PTHR agonists at stimulating cAMP production and βarr recruitment, the 
concentration-response data obtained in the Glosensor cAMP assay and PTHR-βarr BRET assay were fitted to the 
Black-Leff operational model, as shown in eq. 1.  [A] is the agonist concentration, E is the observed signal in each 
assay, KA is the functional affinity of the agonist, and τ is a parameter operationally describing the agonist efficacy.  τ 
is dependent on both the receptor density and the intrinsic efficacy of the agonist in activating cellular pathways.  From 
eq. 1, a single parameter, log(τ/KA), is defined as the transduction ratio, which characterizes the agonist capacity to 
activate a specific pathway.  For curve-fitting purposes, eq. 1 is rewritten into eq. 2, in which R = τ/KA.  For a given 
analogue, the transduction ratio of each signaling pathway, cAMP production or βarr recruitment, was compared to 
that of PTH(1-34) by calculating the difference in their log(τ/KA) values (eq. 3).  The resulting Δlog(τ/KA) values were 
used to determine the bias factor ΔΔlog(τ/KA) by substracting the Δlog(τ/KA) value in the arrestin pathway from that 
in the cAMP pathway (eq. 4).  For each peptide, S.E.M. was calculated for the transduction ratio in both pathways.  
Standard error (S.E.) in the bias factor was calculated by propagating the error in the log(τ/KA) values.  To determine 
whether the bias factor for a given analogue was statistically significant, ΔΔlog(τ/KA) values were compared using 
one-way ANOVA followed by Dunnett’s test.  P<0.05 denotes statistical significance. 
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Figure 8. Recruitment of Endogenous βarr to PTHR Detected by Co-immunoprecipitation. 
HEK293 cells stably expressing HA-tagged PTHR were stimulated with 100 nM of the indicated peptide.  The left 
and right panels of B are from the same blot with unrelated data omitted from the center. 
 
[112].  Both 2 and 3 were ~10-fold biased toward the Gs-mediated signaling pathway versus βarr 
recruitment relative to PTH(1-34), while peptide 1 displayed a more moderate bias.   
Modifications of ABL involving positions 1 and 2 also yielded candidate analogues.  
Peptides 4-6 were very effective at stimulating cAMP production but significantly less effective 
than ABL or PTH(1-34) at recruiting βarrs (Fig. 6B,C).  We evaluated βarr recruitment induced 
by 1, 4, 5, or 6 via co-immunoprecipitation (Co-IP) of endogenous βarr in HEK293 cells stably 
expressing HA-tagged PTHR.  PTH(1-34) effectively induced Co-IP of the PTHR and βarr, while 
agonists 1, 4, 5, and 6 showed impaired interaction (Fig. 8). 
The signaling duration of Gs-biased agonists 1-6 was evaluated with “washout” assays in 
which cells were stimulated with an agonist for a defined period, and then the agonist was washed 
away, and cAMP production was monitored (ligand-off phase) [35, 114].  Although ABL has 
previously been shown to induce cAMP responses that are more transient than PTH(1-34), we 
found that both 4 and 6 performed similarly to PTH(1-34) in this assay at the tested concentration 
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(Fig. 9B).  Interestingly, peptide 1 induced more prolonged signaling relative to PTH(1-34) (Fig. 
9A).   
 To evaluate the location of the cAMP production stimulated by 1, 4, or 6, we introduced 
an excess of PTHR antagonist (D)Trp12,Tyr34-bPTH(7-34) during the washout assay.  We 
hypothesized that this antagonist should compete with agonist molecules for PTHR remaining on 
the cell surface, but the antagonist should not reach internalized agonist-receptor complexes [96, 
115].  For 1, 4, and 6, the presence of antagonist after washout caused a profound decrease in the 
duration and extent of cAMP production (Fig. 9).  In contrast, only a modest drop was observed 
after washout with antagonist for PTH(1-34), which is known to continue stimulating cAMP 
production from endosomes [31].  These observations support the conclusion that biased agonists 
1, 4, and 6 are relatively ineffective at inducing βarr recruitment to the PTHR, which causes 
activated receptors to remain at the cell surface. 
 Blocking endosomal acidification was shown to prolong cAMP production of PTH [44].  
We therefore conducted additional washout experiments with bafilomycin A1 (BA1), an 
inhibitor of endosomal acidification [116], to gain further insight into the signaling profiles of 1, 
4, and 6.  After agonist washout, cells were incubated in a solution containing both BA1 and the 
antagonist.  Inclusion of BA1 after washout had very little effect on the extent of post-washout 
cAMP production induced by 4 or 6 (Fig. 9C), but BA1 caused a substantial increase in post-
washout cAMP production induced by 1, relative to the level observed with the antagonist alone.  
This observation suggests that the single α→β2 replacement at position 5 of PTH(1-34) (to 
generate 1) exerts dual effects on the agonist profile by diminishing βarr recruitment induced by 
1 and rendering 1 susceptible to acidification-induced dissociation from the receptor within 
endosomes.  In contrast to the agonist activity of 1 or ABL, the spatial restriction of cAMP  
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Figure 9. Effect of Competitive Antagonist and BA1 on Signal Duration. 
(a, b) Post-washout cAMP production mediated by 1 nM PTH, 1, 4, or 6 in HEK293 cells stably expressing human 
PTHR. (c) Washout assay data from part a and b presented as area under the curve (AUC); data for measurements 
with BA1 are included.  Data represent mean ± s.e.m. of N≥3 independent experiments.  All the ligand activities are 
normalized to that of PTH(1-34) at 1 nM.  Statistically significant difference using one-way ANOVA (**** P < 
0.0001, *** P < 0.001. ** P < 0.01). 
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production induced by 4 or 6 seems to arise predominantly from their inability to induce receptor 
internalization. 
3.4 Discussion 
We have shown that introducing a single extra CH2 unit into the backbone of a long 
polypeptide agonist can substantially change the signaling profile that results from engagement of 
a class B GPCR.  Moreover, altering the position of the extra CH2 along the backbone can lead to 
different signaling outcomes.  Because this backbone-focused approach maintains the native side 
chain sequence, and because the backbone-modified peptides can be prepared via conventional 
solid-phase synthesis, designing and generating a “test set” of β-containing analogues based on a 
known polypeptide agonist is straightforward.  While displaying high potency and efficacy in 
stimulating cAMP production, β residue-containing peptides 1, 4, and 6 are highly defective for 
βarr recruitment.  When compared to the α peptide prototypes at equivalent concentrations, these 
three α/β peptides induce a longer duration of cAMP production that emanates predominantly from 
receptors at the cell surface.  There is a long-standing belief that sustained cAMP production PTHR 
stimulation will lead to prolonged RANKL activation and bone resorption [117].  However, it is 
unclear at present whether the spatial aspect of cAMP production contributions to the RANKL 
activation.  The highly Gs-biased agonists 4 and 6 could be useful tools to explore questions of this 
type. 
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4.0 Biased GPCR Signaling Reveals Endosomal cAMP as Determinant for Vitamin D 
Homeostasis 
Chapter adapted from: Alex D. White, Lisa J. Clark, Karina A. Peña, Shi Liu, Saifei Lei, Fei Fang, 
Frédéric G. Jean-Alphonse, Zhiqiang Cheng, Chia-Ling Tu, Nicholas Szeto, Kunhong Xiao, 
Samuel H. Gellman, Wenhan Chang, and Jean-Pierre Vilardaga. Biased GPCR signaling reveals 
endosomal cAMP as determinant for vitamin D homeostasis. (manuscript in preparation) 
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4.1 Introduction 
GPCRs are encoded by over 800 individual genes in humans, and their expression in 
various tissues is paramount for proper control of a wide range of physiological processes [118].  
These receptors reside predominantly at the cell surface, where they recognize and respond to an 
impressively diverse catalog of extracellular ligands that range from photons and ions to small 
molecule neurotransmitters and large peptide hormones [1].  To explain how these receptors 
achieve such exquisite specificity in their biological effects, previous reports have described 
receptor and functional selectivity as critical determinants.  Functional selectivity originally 
referred to empirical observations that ligands for the same GPCR can possess differential 
propensities to activate downstream signaling pathways (i.e. biased agonism) [119, 120].  In this 
classical model, GPCR activation was thought to stimulate heterotrimeric G protein signaling 
exclusively from the cell surface in a transient manner due to subsequent recruitment of βarrs, 
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which was proposed to sterically block further G protein coupling and to mediate agonist-induced 
receptor internalization, preventing additional rounds of stimulation by extracellular ligand.  This 
model has been challenged over the last decade by the discovery of several receptors that engage 
in sustained cAMP signaling from early endosomes following endocytosis [31, 53].  Observations 
that the location and duration of Gs-mediated cAMP responses can be dictated in a ligand-
dependent manner for a single GPCR has led to the emergence of spatiotemporal regulation in 
GPCR signaling transduction as a novel property of functional selectivity.  For example, studies 
involving the PTHR have shown that ligands PTH1-34 and its related peptide (PTHrP1-36) stabilize 
distinct receptor conformations that result in cAMP responses that differ markedly in location and 
duration [31, 35, 36].  While both ligands stimulate transient cAMP responses from the cell 
surface, only PTH1-34 causes an additional sustained phase of cAMP generation derived from 
highly stable ligand-receptor-βarr complexes that remain active in early endosomes following their 
internalization [31, 38, 121, 122]. 
 These findings have subsequently been used to explain ligand-specific alterations in PTHR 
biological outcomes observed in vivo, as well as a means for rational drug design.  For example, 
early studies demonstrated that injection of PTH1-34 and PTHrP1-36 into humans causes similar 
enhancement in the formation of new bone but discordant effects on ionized serum Ca2+ and 
vitamin D levels, with lesser effects observed for PTHrP1-36 [45].  Additionally, the PTHrP analog 
abaloparatide, which triggers transient cAMP production confined to the cell surface, has been 
shown to efficiently promote bone formation with a reduced hypercalcemic effect when compared 
to PTH1-34.  Not surprisingly, both PTH1-34 and abaloparatide are FDA-approved for the treatment 
of osteoporosis.  Despite these advancements, whether the spatial versus the temporal dimension 
of cAMP signaling encodes ligand-dependent PTHR biological specificity remains unknown. 
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 Here, we addressed this question by developing a Gs-biased PTHR peptide ligand via 
amino acid epimerization at position 7 of PTH (PTH7d).  We demonstrate that this ligand fails to 
recruit βarrs and stimulates sustained cAMP exclusively from the cell surface.  We subsequently 
utilize mass spectrometry, molecular dynamics simulations, and structural modeling to identify 
underlying determinants in PTHR and βarr that regulate the spatial organization of PTHR-
mediated sustained cAMP.  Studies in mice comparing the actions of PTH7d and a long-acting PTH 
analog that potently promotes endosomal cAMP reveal that homeostatic control of active vitamin 
D levels specifically requires sustained cAMP generation from endosomal compartments.  This 
study highlights the potential for delineating spatial and temporal signaling bias in rational drug 
design and the development of therapeutics with enhanced biological specificity.  
  
4.2 Materials and Methods 
4.2.1 Cell Culture and Transfection 
Cell culture reagents were obtained from Corning (CellGro).  Human embryonic kidney 
cells (HEK293; ATCC, Georgetown, DC) stably expressing the recombinant human PTHR were 
grown in selection medium (DMEM, 5% FBS, 1% penicillin/streptomycin, 500 µg/mL neomycin) 
at 37 °C in a humidified atmosphere containing 5% CO2.  For transient expression, cells were 
seeded on glass coverslips coated with poly-D-lysine in six-well plates and cultured for 24 hours 
prior transfection with the appropriate cDNAs using Fugene-6 (Promega) or Lipofectamine 3000 
(Life Technologies) for 48-72 hours before experiments.  We optimized expression conditions to 
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ensure the expression of fluorescently-labeled proteins was similar in examined cells by 
performing experiments in cells displaying comparable fluorescence levels. 
4.2.2 Chemicals 
Forskolin (#344270) was purchased from EMD-Millipore. 
4.2.3 Peptide Synthesis, Purification, and Quantification 
PTH(1-34), PTH(1-34)TMR, and LA-PTH were synthesized and characterized as previously 
described [44]. 
 (D)-Leu(7)-PTH(1-34) was synthesized by microwave-assisted reactions on NovaPEG 
Rink amide resin.  For each coupling step, the resin was treated with 4 equivalents of protected 
amino acid, 4 equivalents of HATU, and 8 equivalents of N,N-diisopropylethylamine (DIEA) in 
DMF.  Fmoc deprotection was carried out by using 20% (v/v) piperidine with 0.1 M HOBT in 
DMF.  Upon completion of synthesis, the peptide was cleaved from the resin using a solution of 
94% trifluoroacetic acid (TFA), 2.5% H2O, 2.5% 1,2-ethanedithiol (EDT), and 1% 
triisopropylsilane (TIS).  After cleavage, the crude peptide was precipitated by addition of cold 
diethyl ether.  The precipitated material was purified by preparative HPLC.  Peptide purity was 
assessed by UPLC (BEH C18 stationary phase, 2.1 mm x 100 mm, the solvent gradient was 10-
60% acetonitrile over 5 minutes), and peptide mass was checked by MALDI-TOF MS.  The 
peptide reported here was >95% pure as determined by UPLC.  Since (D)-Leu(7)-PTH(1-34) 
contains one tryptophan in its sequence, the peptide concentration was determined by UV 
spectroscopy using the absorbance at 280 nm (the molecular extinction coefficient of tryptophan 
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at 280 nm is 5690 M-1cm-1).  After concentration determination, the peptide was aliquoted, 
lyophilized to dry power, and stored at -20 °C. 
4.2.4 Plasmids 
DNA constructs encoding for PTHRYFP, PTHRCFP, and βarr-2YFP were previously 
described by the Vilardaga lab [31, 63, 123].  βarr-1Rluc8 was provided by Dr. Zachary Freyberg 
(University of Pittsburgh). 
4.2.5 Co-immunoprecipitation 
HEK293 cells stably expressing HA-PTHR and cultured on a 10-cm dish were stimulated 
with PTH(1-34) or analogues at 100 nM at 5 minutes.  Cells were then washed with ice-cold PBS 
prior to cross-linking for 2 hours with DSP (Covachem, #13301) in PBS at 4 °C.  The reaction was 
stopped by addition of 10 mM Tris-HCl for 10 minutes and cell lysates were prepared using lysis 
buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.4, 140 mM NaCl, 0.5 mM EDTA) containing 
protease and phosphatase inhibitors (Roche, #11873580001).  Protein concentration was 
determined using BCA protein assay kit (ThermoFisher, #23225), and lysates were incubated with 
anti-HA agarose antibody beads (Sigma-Aldrich; #A2095 clone HA-7) overnight at 4 °C.  Elution 
was done using LDS loading buffer (Life Technologies) and samples loaded on 10% SDS-PAGE 
and transferred to nitrocellulose membrane.  We used antibodies against HA (Covance, clone 
16B12), and βarr-1/2 (Cell Signaling; #4674, clone D24H9).  Immunoreactive bands were 
visualized with Luminata Forte (EMD Millipore) and autoradiography film.   
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4.2.6 cAMP Accumulation Assay 
HEK293 cells stably expressing the Glosensor cAMP reporter and human PTH1R were 
cultured in DMEM supplemented with 10% FBS.  Cells were seeded into 96-well corning plates 
and used for cAMP assays after forming a confluent monolayer.  Upon the removal of culture 
medium, the intact cells in 96-well plates were incubated in CO2-independent medium containing 
D-luciferin (0.5 mM) for 20 minutes at room temperature.  After this period, cells in each well 
were treated with peptides at various concentrations, and luminescence resulting from cAMP 
production was measured for 30 minutes on a BioTek Synergy 2 plate reader.  The peak 
luminescence signaling (which usually appeared 14-20 minutes after peptide addition) were used 
to generate concentration-response curves.  The concentration-response curves were fit to the data 
by using the sigmoidal dose-response equation in Prism 6.0.  Reported EC50 and Emax values 
represent mean ± s.e.m of n ≥ 3 independent measurements. 
4.2.7 Washout Assay 
For the washout experiments, cells preloaded with D-luciferin were treated with medium 
(vehicle) or agonists at the concentration of 1 nM for 14 minutes (ligand-on phase).  After this 
period, the medium in each well was removed and the cells were rinsed twice with CO2-
independent medium to remove unbound ligand.  After the addition of D-luciferin-containing fresh 
medium to each well, the luminescence was recorded for an additional 150 minutes (ligand-off 
phase).  For competitive antagonist-modified washout assays, the experimental protocol was as 
described above except that the competitive antagonist (0.5 µM) was introduced during the ligand-
off phase.  For Bafilomycin A1 (BA1) and competitive antagonist-modified washout experiments, 
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the cells were pretreated with medium containing 0.5 mM D-luciferin for 20 minutes in the 
presence or absence of 50 nM BA1.  After the ligand-on phase, as described above, the rinsed cells 
were incubated in D-luciferin-containing fresh medium with or without BA1 and competitive 
antagonist, and luminescence was monitored for 150 minutes. 
4.2.8 cAMP Time-courses and βarr Recruitment by FRET 
cAMP was assessed using FRET-based assays.  Cells were transiently transfected with the 
FRET-based biosensor Epac1CFP/YFP [61] for measuring cAMP.  Measurements were performed 
and analyzed as previously described [62].  In brief, cells plated on poly-D-lysine coated glass 
coverslips were mounted in Atoofluor cell chambers (Life Technologies), maintained in a HEPES 
buffer containing 150 mM NaCl, 20 mM HEPES, 2.5 mM KCl, 1 mM CaCl2, 0.1% BSA, and pH 
7.4 and transferred on the Nikon Ti-E equipped with an oil immersion 40X numerical aperture 
1.30 Plan Apo objective and a moving stage (Nikon Corporation).  CFP and YFP were excited 
using a mercury lamp.  Fluorescence emissions were filtered using a 480 ± 20 nm (CFP) and 535 
± 15 nm (YFP) filter set and collected simultaneously with a LUCAS electron-multiplying charge-
coupled device camera (Andor Technology) using a DualView 2 (Photometrics) with a beam 
splitter dichroic long pass of 505 nm.  Fluorescence data were extracted from a single cell using 
Nikon Element Software (Nikon Corporation).  The FRET ratio for single cells was calculated and 
corrected as previously described [63].  Individual cells were perfused with buffer or with ligand 
for the time indicated by the horizontal bar.   
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4.2.9 βarr Recruitment by BRET 
CHO-FlpIn cells transfected with PTH1R-Rluc8 and βarr-1venus or βarr-2venus were cultured 
in DMEM supplemented with 10% FBS and 0.7 mg/mL hygromycin-B.  Cells were seeded into 
96-well plates at a density of 4x104 cells/well and cultured for 24 hours before the BRET assay.  
Cells were rinsed twice with DPBS to remove traces of phenol red and incubated in fresh DPBS 
containing coelenterazine-h (at a final concentration of 5 µM) at 37 °C for 10 minutes.  After this 
period, cells in each well were treated with peptides at various concentrations and BRET readings 
were collected for 25 minutes on a BioTek Synergy 2 plate reader with 460/40 and 528/20 nm 
emission filters.  The BRET signal was calculated by subtracting the ratio of 528/20 emission over 
460/40 emission for vehicle-treated cells from the same ratio for ligand-treated cells.  The peak 
BRET signals (which usually appeared within the initial 5 minutes after the peptide addition) were 
used to generate concentration-response curves.  The concentration-response curves were fit to the 
data by using sigmoidal dose-response equation in Prism 6.0.  Reported EC50 and Emax values 
represent mean ± s.e.m of n ≥ 3 independent experiments.  
4.2.10 Saturation and Competition Binding Using PTHTMR 
HEK293 cells were transiently transfected with HA-PTHR and seeded in 96-well plates. 
Approximately 48 h after transfection, cells were incubated in HEPES buffer (137 mM NaCl/5 
mM KCl/1 mM MgCl2/20 mM HEPES/0.1% BSA pH 7.4) for 1 h at 4 °C, followed by 2 h 
incubation at 4 °C in the presence of ligand. Increasing concentration of TMR-labeled PTH 
(PTHTMR) were utilized for saturation binding, while competition binding experiments used a 
constant PTHTMR concentration (31.6 nM) with increasing amounts of unlabeled PTH. Cells were 
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washed twice with the same buffer, and fluorescence intensities were recorded at 580 ± 20 nm 
using an excitation wavelength of 525 ±20 nm on a Tecan Spark 20M multimode microplate 
reader. Nonspecific binding was determined using 1 μM of unlabeled ligand. Data were 
subsequently analyzed using Graphpad Prism 7.0 (GraphPad Software Inc., La Jolla, CA). 
4.2.11 Receptor Internalization and Recycling 
Live-imaging trafficking of PTHRSEP was done as described [64] using a Nikon A1 
confocal microscope.  Briefly, HEK293 cells stably expressing a pH-sensitive GFP variant, 
superecliptic pHluorin, inserted in the N-terminal domain of the human PTHR were seeded on 
glass coverslips coated with poly-D-lysine (Sigma #P7280) for 24 hours.  Experiments were 
carried out at 37 °C in FRET buffer used for cAMP experiments.  Cells were stimulated by ligand 
for 1 minute then washed out to allow recycling.  Images were acquired every 30 seconds. 
4.2.12 Mouse Studies 
To test the impact of PTH7d, LA-PTH, and PTHWT (Bachem, Torrance, CA, Cat#H-5460) 
on serum and skeletal parameters, 3-month-old male C57BL/6J (C57/B6) mice (Jackson 
Laboratory, Stock No: 000664) were ear-tagged for identification, randomly assigned to groups, 
and injected daily with ligand (40 µg/kg body weight/injection) for 4 weeks after the mice were 
acclimated with house environment for 2 weeks.  In this study, blood was sampled via retroorbital 
route under isoflurane anesthesia after 2 hours of the last drug injection.  Mice were allowed to 
recover before another blood collection by cardiac puncture and bone collection from the mice 
euthanized by isoflurane overdose 24 hours after the last drug injection.  Serum Ca2+ and phosphate 
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levels were assessed by an ACE Axcel bioanalyzer (Alfa Wassermann, West Coldwell, NJ) and 
skeletal parameters of distal femurs were assessed by an SCANCO µCT 50 scanner and analytic 
software (Scanco USA, Inc., Wayne, PA, USA) as detailed previously [124].  In a separate time-
course study, a different group of mice were injected with a single dose of PTH7d or LA-PTH for 
different time points before euthanization.  Their serum 1,25D levels were assessed by an ELISA 
kit (AC-62F1; Immunodiagnostic systems, Tyne & Wear, United Kingdom) according to the 
manufacturer instructions.  All mice were kept in a climate-controlled room (22 °C; 45-54% 
relative humidity) with a 12-hour light/12-hour dark cycle.  Water and standard chow (1.3% 
calcium and 1.3% phosphate) were given ad libitum.  All animal experiments (Protocol #18-013) 
were approved and performed according to guidelines of the Institutional Animal Care and Use 
Committee at the San Francisco Department of Veterans Affairs Medical Center. 
4.2.13 Pharmacokinetic Analysis 
Bioactive LA-PTH or PTH7d peptide content of blood plasma was assessed by applying 5 
µL of plasma (supplemented with protease inhibitors) to the HEK293-derived cell line GP2.3 in 
which human PTHR and the luciferase-derived glosensor cAMP reporter were stably expressed.  
Cells were seeded into 96-well white plates and assayed 24 hours later in CO2-independent culture 
medium (Life Technologies, Carlsbad, CA, USA) containing 0.1% BSA.  Cells were pre-incubated 
with D-luciferin (0.5 mM) for 2 hours, then blood plasma samples were added and cAMP-
dependent luminescence was measured at 2-minute intervals.  For each well, the maximum 
luminescence observed, which typically occurred 10-20 minutes after sample addition, was used 
to establish relative bioactive peptide.   
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4.2.14 MD simulations 
System preparation.  The 3.0 Å cryo-EM structure of LA-PTH-PTHR-Gs-Nb35 complex 
(PDB 6NBF) [109] was used to generate initial PTHR models.  I-TASSER was then used to model 
flexible loops absent in the cryo-EM structure:  ECD residues 56-104, ECL1 residues 247-275, 
and ICL3 residues 394-398 [125-127].  In PyMOL, structures of Gs, Nb35, palmitic acid, and 
cholesterol were removed.  LA-PTH residues were mutated to the corresponding PTHWT residues, 
as necessary, using the PyMOL Mutagenesis Wizard.  The chirality of L7 in the PTHWT model 
was changed in PyMOL to generate the PTH7d model.  Each initial model was oriented in a model 
membrane using the Orientations of Proteins in Membranes (OPM) PPM Server [128].  Using 
oriented models, inputs for Nanoscale Molecular Dynamics (NAMD) were generated using 
CHARMM-GUI Membrane Builder [129-135].  Disulfide bonds Cys48-Cys117, Cys108-Cys148, 
Cys131-Cys170, and Cys281-Cys351 were specified to ensure correct formation.  A 
heterogeneous lipid bilayer consisting of 75% POPC and 25% cholesterol was assembled around 
the receptor model using the Replacement Method.  The system was solvated in a box of TIP3P 
waters, and ions were added to a concentration of 150 mM NaCl using Monte Carlo sampling. 
MD simulations.  All-atom simulations were performed in triplicate for PTHWT ̶ PTHR and PTH7d ̶ 
PTHR simulations using NAMD with the CHARMM36m force field [136, 137].  Prior to 
production simulations, 10,000 steps of conjugate gradient energy minimization were performed 
followed by 0.675 ns equilibration in which restraints were applied and then slowly released over 
six steps following the protocol established by the CHARMM-GUI group [136].  Next, 200 ns 
production simulation with 2 fs timestep was performed.  Non-bonded interactions were cut off at 
12.0 Å, and van der Waals force switching was applied between 10.0 and 12.0 Å.  Langevin 
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dynamics and Langevin piston were used to maintain temperature at 303.15 K and pressure at 1 
atm. 
MD trajectory analysis.  MD trajectories were analyzed in Visual Molecular Dynamics 
(VMD) and PyMOL [138].  PTHR snapshots were aligned using receptor TM helices (PTHRTMD 
without ECLs or ICLs:  residues 180 to 211, 218 to 246, 280 to 311, 317 to 343, 359 to 392, 399 
to 425, 435 to 460).  PTH Glu4 hydrogen bond analysis was performed using HBonds Plugin in 
VMD.  Number of hydrogen bonds throughout the trajectories was plotted in GraphPad Prism. 
4.2.15 Structural Modeling 
The model of PTHR bound to βarr-1 was generated using a snapshot of PTHWT ̶ PTHR 
after 200 ns simulation and the crystal structure of rhodopsin bound to mouse visual arrestin-1 
(PDB 4ZWJ).  PyMOL was used to perform structural, sequence-independent alignment of the 
TMD of PTHR (residues 180 to 460) to the TMD of rhodopsin (residues 34 to 305, RMSD = 5.193 
Å).  A homology model of βarr-1 in the receptor core conformation was generated in SWISS-
MODEL using the structure of visual arrestin-1 as a template [139, 140].  The βarr-1 model was 
aligned with visual arrestin-1 in PyMOL and PTH7d ̶ PTHR snapshots were then aligned with 
PTHWT ̶ PTHR.  Distances between PTHR Val412 and βarr-1 Leu73 throughout the trajectories 
were calculated in VMD and plotted in GraphdPad Prism. 
4.2.16 1-α(OH)ase protein expression 
MDCK cells stably expressing HA-PTHR were polarized on 24 mm Transwells (Corning) 
with 0.4 µm pore size.  Polarized cells were basolaterally stimulated with 30 nM LA-PTH or 30 
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nM PTH7d diluted in growth media, with or without FBS, for 4 or 8 hours or left untreated.  After 
stimulation, cells were lysed in buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 
10% glycerol, and 1% IGEPAL (Sigma), supplemented with protease and phosphatase inhibitors, 
as described previously [141].  Briefly, transwells were washed in cold PBS and then membranes 
were cut out of their plastic supports and put in a microcentrifuge tube with 300 µL lysis buffer.  
Membranes were vortexed and incubated in rotation at 4 °C for 30 minutes.  Lysates were then 
centrifuged at maximum speed for 10 minutes in a benchtop refrigerated centrifuge.  Supernatants 
were transferred to a clean tube.  Protein concentration was measured using BCA protein assay kit 
(ThermoFisher, #23225).  For Western blot analysis, 10 µg of lysates were loaded per well in a 
10% gel.  Gels were transferred to a nitrocellulose membrane and blocked in TBS-T with 5% milk.  
For detection of 1-α(OH)ase, membranes were blotted with anti-CYP27b1 polyclonal antibody 
(Novus Biologicals #NBP2-29942) at 1:1000 dilution.  Anti-GAPDH monoclonal antibody (Santa 
Crus Biotechnologies #sc-3223) at 1:1000 dilution was used as loading control.  HRP-conjugated 
antibodies (Dako Denmark, Denmark) were used as secondary antibodies.  Immunoreactive bands 
were visualized with immobilon forte western HRP substrate (EMD Millipore, #WBLUF0100).  
Band intensity quantification was performed using ImageJ software (NIH). 
4.2.17 Photo-crosslinking experiments 
HEK293 cells (2x106) were seeded on poly-D-lysine coated 10-cm dishes, and 24 hours 
later p-benzoyl-L-phenylalanine (Bpa) was added to the medium for 1 hour prior to transfection.  
Cells were co-transfected with three plasmids:  one plasmid encoding for PTHR, the second 
plasmid containing the gene of HA-tagged βarr-1 with a TAG codon substituting for the triplet 
encoding Leu73, and the last plasmid (pIRE4-Bpa) encoding for the orthogonal pair incorporation 
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Bpa (EcBpaRS/BstYam).  Approximately 24-36 hours after transfection, cells were stimulated 
with 200 nM PTHWT or PTH7d for 10 minutes, washed twice with cold PBS, and irradiated for 15 
minutes in PBS using UVP crosslinker (Analytik Jena) with 2000 x 100 microjoules per cm2 
energy exposure at a distance of 2.5 cm.  Cell lysates were prepared with lysis buffer were prepared 
in buffer containing 1% Triton X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, and 2 mM EDTA, 
and protein concentration was determined using BCA protein assay kit (ThermoFisher, #23225).  
Lysates were incubated with PierceTM anti-HA agarose beads (ThermoFisher, #26181) overnight 
at 4 °C.  Beads were washed 4 times with lysis buffer and eluted with 2X loading buffer.  We used 
antibodies against HA (Covance, clone 16B12) and βarr-1/2 (Cell Signaling, #4674, clone 
D24H9).  Immunoreactive bands were visualized with immobilon forte western HRP substrate 
(EMD Millipore, #WBLUF0100). 
4.2.18 Stable Isotope Labeling With Amino Acids in Cell Culture (SILAC) 
We used the HEK293 cell line stably expressing the human HA-tagged PTHR previously 
generated in our lab [51].  Three pools of HA-PTHR/HEK293 cells were maintained side-by-side 
in “light”, “medium”, or “heavy” SILAC medium.  The SILAC media were prepared from custom-
ordered DMEM powder without arginine, lysine, and leucine (Gibco, formula #03-5080EB).  
[2H4]-L-lysine (50 mg/liter) and [
13C6]-L-arginine (25 mg/liter) (Cambridge Isotope Laboratories) 
were added to “medium”, [13C6, 15N2]-L-lysine (50 mg/liter) and [13C6, 15N4]-L-arginine (25 
mg/liter) (Cambridge Isotope Laboratories) were added to “heavy”, and equal concentrations of 
conventional lysine and arginine were added to “light”.  All versions were supplemented with L-
leucine (104 mg/liter), L-proline (10 mg/liter), 10% dialyzed FBS (Hyclone), 1% 
penicillin/streptomycin, and G418 (150 mg/mL).  The SILAC cells were cultured for at least six 
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doublings until the isotope incorporation rates in “medium” and “heavy” cells were higher than 
95%.  The SILAC cells were then expanded.  When the cells reached ~80% confluence, they were 
serum-starved for 4 hours.  To map the phosphorylation sites on the PTHR induced by PTHWT or 
PTH7d, “light” cells were treated with 30 nM PTHWT for 5 minutes and “medium” cells were 
treated with 30 nM PTH7d for 5 minutes before harvesting (“heavy” cells served as non-treated 
control).  Equal numbers of “light”, “medium”, and “heavy” cells (generally six 150-mm culture 
dishes for each) were mixed, flash-frozen in liquid nitrogen, and stored at -80 °C.  The SILAC 
experiments were repeated three times. 
4.2.19 HA-PTHR Isolation, Digestion, and Peptide Desalting 
HA-PTHR was isolated from SILAC cells using PierceTM anti-HA agarose beads (Thermo 
Fisher Scientific, #26181).  Briefly, crude membrane fractions were prepared from equally mixed 
(“light”:“medium”:“heavy” = 1:1:1) as previously described [142, 143].  HA-PTHR was then 
extracted from crude membrane preparations with buffer containing 20 mM tris-HCl pH 8.0, 100 
mM NaCl, 2 mM EDTA, 1% DDM, and protease/phosphatase inhibitors.  HA-PTHR was isolated 
from extraction solution by incubating with 200 µL anti-HA beads with rotation at 4 °C for 4 
hours, and receptor was eluted with 100 µL 2X SDS-PAGE buffer (containing 100 mM DTT).  
The receptor was then alkylated with 30 mM iodoacetamide in the dark for 30 minutes at room 
temperature, and samples were then subjected to SDS-PAGE.  Protein bands corresponding to HA-
PTHR were excised from the gel for in-gel protein digestion.  Tryptic digestion of HA-PTHR was 
performed as previously described [70, 144].  Briefly, excised gel bands were chopped into small 
pieces and de-stained with 50 mM ammonium bicarbonate in 50% acetonitrile.  Sequence grade 
trypsin (10 ng/µL, Promega) in 50 mM ammonium bicarbonate (pH 8.0) was then added to the 
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tubes to cover the de-stained gel pieces.  The tryptic digestion reactions were incubated at 37 °C 
overnight.  An equal volume of 100% acetonitrile was added to the digested gel samples for peptide 
extraction and repeated three times.  The extracted peptides were pooled into a pre-washed protein 
LoBind tube (Fisher, #13698793) and then dried under vacuum on a SpeedVac evaporator.  The 
peptide samples were desalted with handmade Stage Tips was previously described [70].  The 
desalted peptides were lyophilized with a SpeedVac evaporator, reconstituted in 0.1% 
trifluoroacetic acid, 2% acetonitrile, and 25 mM citrate, and subjected to LC-MS/MS analysis. 
4.2.20 MS and Data Analyses 
LC-MS/MS analyses were performed on a Thermo Scientific LTQ Orbitrap Velos mass 
spectrometer with a Finnigan Nanospray II electrospray ionization source.  The peptide samples 
were loaded onto a nanoViper Compatible PicoChip Column (New Object, #1PCH7515-
105H354-NV) and separated with a Waters nanoACQUITY UPLC System.  Instrument control 
and primary data processing were done with the Xcalibur software package.  The LTQ Orbitrap 
Velos was operated in data-dependent mode using a TOP10 strategy [145].  MS/MS spectra were 
searched with the SEQUEST algorithm against composite database containing the human HA-
PTHR sequence or HA-PTHR with its interacting proteins, as well as their reverse sequences.  
Search parameters allowed for three missed tryptic cleavages, a mass tolerance of ±80 ppm, a static 
modification of 57.02146 daltons (carboxyamidomethylation) on cysteine, and up to eight dynamic 
modifications:  79.96633 daltons (phosphorylation) on serine, threonine, and tyrosine; 15.99491 
daltons (oxidation) on methionine; 6.02012 daltons or 10.00827 daltons on arginine; and 5.00709 
daltons or 8.01420 daltons on lysine.  Search results were filtered to include <1% matches to 
reverse sequences by restricting the mass tolerance window, and setting thresholds for Xcorr and 
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dCn’ (defined as the normalized difference between Xcorr values of the top-ranked candidate 
peptide and the next candidate with a different amino acid sequence).  Matches for 
phosphopeptides were validated manually with special consideration of intense fragment ions 
formed through cleave N-terminal to proline residues and neutral losses of phosphoric acid.  
Peptide quantification was performed with the Vista program [146] as well as by manual 
calculation with Qual Browser (version 3.0.63).  In brief, the theoretical mass of “light”, 
“medium”, and “heavy” variants of each peptide was calculated and used to identify ion peaks in 
the high mass accuracy precursor scans for each.  The intensity of the peaks was used to construct 
ion chromatograms.  For each isotopic variant, the peak height and background-subtracted area 
under the curve were used to calculate the “light” to “heavy” (PTHWT:control) and “medium” to 
“heavy” (PTH7d:control) abundance ratios. 
4.2.21 Statistical Analysis 
Data were processed using Excel 2013 (Microsoft Corp. Redmond, WA) and Prism 7.0 
(GraphPad Software Inc., La Jolla, CA).  Data are expressed as mean ± SEM.  Curves were fit to 
the data using a four-parameter, non-linear regression function.  Statistical analyses were 
performed using unpaired, 2-tailed Student’s t tests for comparisons between 2 groups and one- or 
two-way ANOVA with Dunnett tests for multiple group comparisons. 
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4.3 Results 
We have previously shown that translocation of PTH ̶ PTHR signaling complexes from the 
cell surface to early endosomes is βarr-dependent [38, 41].  We reasoned that a PTHR ligand that 
stimulates cAMP production but fails to recruit βarr would cause a shift in sustained cAMP 
generation from endosomes to the cell surface, thus permitting determination as to how the cellular 
localization of signaling responses influences PTHR biology.  To this end, we explored 
modifications of residues in the N-terminal region of PTH1-34 in an effort to generate a Gs-biased 
agonist that promotes prolonged receptor activation and retention of ligand-receptor complexes at 
the cell surface.  Accordingly, we determined that the diastereomer containing D-Leu, rather than 
L-Leu, at position 7 of (PTH7d) provides the desired bias.  This modification did not alter binding 
affinity in equilibrium competition assays utilizing tetramethylrhodamine (TMR)-labeled PTH as 
reporter ligand (Fig. 10A), nor did it cause changes in the potency (EC50) or maximal efficacy 
(Emax) of cAMP production in luciferase-based accumulation assays (Fig. 10B, black circles).  
Time-course experiments of the cAMP response using the Fӧrster resonance energy transfer 
(FRET)-based sensor EPACCFP/YFP revealed that PTH7d induces sutained cAMP responses upon 
ligand washout that are indistinguishable in magnitude and duration from wild-type PTH1-34 
(hereafter referred to as PTHWT (Fig. 10C).  In contrast, PTH7d displayed markedly impaired 
recruitment of βarrs compared to PTHWT measured by bioluminescence resonance energy transfer 
(BRET) in cells stably expressing PTHRRluc8 and venus-tagged βarr-1 or βarr-2 (Fig. 10B, 
orange/green circles), and this effect was confirmed by FRET time-course experiments in cells 
transiently expressing PTHRCFP and βarr-2YFP (Fig. 10D).  These data confirm that PTH7d 
represents a Gs-biased PTHR ligand that induces sustained cAMP responses independently of βarr 
recruitment. 
 68 
 
Figure 10. Characterization of Signaling by PTH7d. 
(a) Competition binding assays at equilibrium was performed using tetramethylrhodamine (TMR)-labeled PTH as 
reporter ligand and HEK293 cells stably expressing HA-tagged PTHR.  Data are the mean ± s.e.m. of N=3 independent 
experiments with triplicate wells for each concentration point. (b) Concentration-response curves for PTH (left) or 
PTH7d (right) in cAMP accumulation (black) or βarr recruitment (orange, green) assays.  Data are the mean ± s.e.m. 
of N=5 independent experiments with triplicate wells for each concentration point.  (c) Averaged cAMP time-course 
responses in HEK293 cells stably expressing PTHR following brief stimulation with 10 nM PTH or PTH7d.  Data are 
the mean ± s.e.m. of N=3 independent experiments with n = 20-26 cells per experiment.  (d) Time course (left) and 
integrated response (right) of βarr recruitment measured by FRET in HEK293 cells transiently expressing PTHRCFP 
and βarr2YFP following brief stimulation with 10 nM PTH or PTH7d.  Data are the mean ± s.e.m. of N=3 independent 
experiments and n = 28-33 cells per experiment (**P = 0.002).   
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We next examined the location of PTH7d signaling complexes.  We have previously shown 
that the sustained phase of PTHWT-mediated cAMP generation from endosomes requires the 
formation and internalization of signaling complexes comprised of ligand-bound receptor, βarr, 
and Gβγ subunits [38, 41].  Blockade of receptor internalization by expression of a dominant-
negative dynamin mutant (DynK44A) led to significantly reduced cAMP responses induced by 
PTHWT, while those for PTH7d were unaffected (Fig. 11A).  Additionally, live-cell confocal 
microscopy experiments revealed that PTH7d fails to induce the subcellular co-localization of βarr-
2YFP and GβγCFP that is observed with PTHWT and a long-acting analog (LA-PTH) previously 
shown to potently induce sustained cAMP signaling from endosomes [79] (Fig. 11B).  
Furthermore, real-time analysis of receptor trafficking in cells stably expressing PTHR N-
terminally tagged with superecliptic pHluorin (SEP), a pH-sensitive GFP variant, showed only 
modest receptor internalization upon PTH7d stimulation when compared to PTHWT and LA-PTH 
(Fig. 11C).  We subsequently confirmed that prolonged cAMP generation observed with PTH7d is 
derived from receptor that is retained at the cell surface, as inclusion of a cell-impermeable PTHR 
antagonist (D-Trp12, Tyr34-bPTH7-34) in the washout buffer completely abolished the sustained 
phase of PTH7d-mediated cAMP generation (Fig. 11D) but had no effect in analogous experiments 
using PTHWT or LA-PTH (Fig. 11E,F).  Collectively, our signaling characterization data indicate 
that amino acid epimerization at position 7 of PTH results in a Gs-biased peptide ligand that differs 
from the wild-type hormone solely by the cellular localization of active signaling complexes 
involved in sustained cAMP responses.   
Given the well-established importance of βarr coupling to the PTHR in permitting 
sustained cAMP generation by PTHWT, we next sought to investigate the molecular mechanisms 
that underlie the relative inability of PTH7d to promote this interaction, as well as its consequences  
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Figure 11. Localization of Signaling Complexes. 
(a) Time courses (left and center panels) and integrated (right panel) cAMP responses calculated by area under the 
curve in cells expressing a dominant-negative dynamin mutant (DynK44A) tagged with RFP compared to control 
cells.  Data are the mean ± s.e.m. of N = 3 independent experiments with n = 15-32 cells per experiment (***P = 
0.0003).  (b) Fluorescence micrographs corresponding to the merged channel data of HEK293 cells co-transfected 
with GβγCFP (red) and βarr-2YFP (green).  Images were recorded at 30 s intervals for 30 minutes after a brief challenge 
with 100 nM PTHWT, LA-PTH, or PTH7d.  Scale bar = 5 µm.  (c) Time courses of internalization and recycling of 
PTHR tagged with superecliptic pHluorin (SEP) in response to ligand, measured by time-lapse confocal microscopy 
with images acquired every 30 seconds.  The baseline was established for 5 minutes, then cells were stimulated with 
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100 nM PTH, PTH7d, or LA-PTH for 30 seconds.  Data are the mean ± s.e.m. of N=3 independent experiments with 
n = 11-14 cells per experiment.  (d,e) cAMP time-course experiments after washout of PTH7d (d) or LA-PTH (e) in 
the presence (black curve) or absence (blue curve) of cell-impermeable competitive antagonist.  Data are the mean ± 
s.e.m. of N=3 independent experiments.  (f) Integrated cAMP responses from panels d/e in the presence or absence of 
cell-impermeable competitive antagonist for PTH, LA-PTH, or PTH7d (****P = 0.00000002). 
 
 
for both cell biological and physiological processes.  Recruitment of βarrs to activated GPCRs is 
thought to occur following phosphorylation of serine/threonine residues within intracellular 
receptor domains, specifically the third intracellular loop (ICL3) and C-terminal tail, by GPCR 
kinases (GRKs).  Furthermore, studies in recent years have proposed that receptor phosphorylation 
status serves as the foremost determinant for GPCR ̶ βarr interactions, a paradigm commonly 
referred to as the phosphorylation barcode hypothesis [147-149].  Accordingly, we examined 
whether PTHWT and PTH7d trigger distinct phosphorylation patterns in the PTHR that differentially 
permit distinct interactions with βarrs by performing Stable Isotope Labeling by Amino acids in 
Cell culture (SILAC)-based proteomics.  We identified 10 phosphorylation sites located in the C-
terminal tail and ICL3 in response to 5 minute stimulation with PTHWT or PTH7d at a concentration 
of 30 nM (Fig. 12A), and the quantitative changes of these phosphorylation events are listed in 
Fig. 12B.  While βarr recruitment is considered driven by receptor phosphorylation status [142], 
we found no differences in the sites or extent of phosphorylation between PTHWT and PTH7d 
treatments (Fig. 12C).  Despite previous work suggesting that PTHR  ̶βarr interactions rely upon 
receptor phosphorylation status [150], this finding supports that alterations in βarr recruitment 
observed for PTHWT and PTH7d occur in a phosphorylation-independent manner. 
 In an effort to elucidate the mechanistic basis by which epimerization of Leu7 in PTH 
precludes association of βarr with the receptor, we subsequently utilized molecular dynamics (MD)  
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Figure 12. SILAC-based quantitative phosphorylation analysis of PTH. 
(a) Summary of intracellular phosphorylation sites in PTHR and corresponding changes in response to 30 nM PTH or 
PTH7d stimulation.  Phosphorylation sites were determined by LC-MS/MS and indicated in red in the snake view map 
of the PTHR.  The fold changes corresponding to the extents of phosphorylation were determined by SILAC-based 
quantitative LC-MS/MS analysis as described in the methods sections.  (b,c) List of phosphopeptide sequences 
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identified (b) and fold changes (c) determined by SILAC-based quantitative LC-MS/MS analysis.  Since isomeric 
single phosphorylated peptides (489SGSSSYSYGPM*VSHTSVTNVGPR511) with phosphorylation at different 
positions co-eluted from the LC column during chromatographic separation, the quantitative analysis reflects a 
summary of a mixture of these co-eluted single phosphorylated peptides.  Data are the mean ± s.d. of N = 3 independent 
experiments (NS = not significant by two-way ANOVA). 
 
simulations and structural modeling to assess PTHR conformations stabilized upon binding of 
either PTHWT or PTH7d.  We utilized the recently reported 3.0 Å cryo-EM structure of active PTHR 
bound to Gs and LA-PTH (PDB 6NBF) [109] to generate initial models of PTH
WT- and PTH7d-
bound PTHR for triplicate 200 ns MD simulations.  In the initial PTH7d ̶ PTHR model, D-Leu7 is 
unfavorably close to neighboring transmembrane helix (TM) 7 residues Trp437 and Met441 of the 
receptor (Fig. 13A), and simulations revealed that the D-Leu7 side chains shifts to mirror L-Leu7 
nonpolar interactions in the PTHWT ̶ PTHR model (Fig. 13B).  We found that this shift induces a 
kink in the PTH7d helix toward TM6 (Fig. 13B), which subsequently permits additional polar 
interactions between Glu4 of PTH7d and PTHR residues that are not observed for PTHWT (Fig. 
13C, 13D).  In the active-state cryo-EM structure of PTHR, Glu4 promotes an extensive polar 
interaction network that stabilizes the outward kink of TM6 that is considered prerequisite for 
coupling to G proteins [109, 122].  The increased polar contacts by Glu4 of PTH7d further extend 
this polar interaction network relative to PTHWT-bound receptor. 
 These observations, combined with previous reports that an inward movement of TM6 is 
essential for efficient βarr coupling [151], led us to hypothesize that the increased stabilization of 
the outward TM6 kink by PTH7d relative to PTHWT may provide the structural basis for differences 
in βarr recruitment.  To test this possibility, we generated a homology model of βarr-1 using the 
conformation of visual-arrestin-1 bound to rhodopsin (PDB 4ZWJ) as a template [139, 140].  We  
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Figure 13.  Molecular changes induced by PTH7d. 
(a) PTHWT and PTH7d are colored cyan and wheat, respectively.  PTHWT- and PTH7d-bound receptor are colored dark 
green and violet, respectively.  PTH Leu7 and receptor residues within 4 Å of Leu7 are shown as sticks.  The left panel 
shows initial MD models of PTHWT  ̶ PTHR and PTH7d ̶ PTHR.  In the initial model of PTH7d ̶ PTHR, D-Leu7 is 
unfavorably close to PTHR residues W437 and M441.  The right panel shows MD models after 200 ns, where the D-
Leu7 side chain has shifted to promote more favorable interactions with nonpolar residues in TM1 and TM7.  (b) 
Snapshots of PTHWT and PTH7d peptide helices at the start (0 ns) and end (200 ns) of MD simulations.  PTH Leu7 
side chain is shown as sticks.  At 200 ns, note the break in the PTH7d helix and the resulting outward push of the 
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peptide N-terminus.  (c) Polar contacts between PTH Glu4 and receptor residues.  Residues interacting with PTHWT 
Glu4 are green sticks, and interactions are cyan dashes.  Residues interacting with PTH7d Glu4 are light pink sticks, 
and interactions are black dashes.  (d) Number of hydrogen bonds between Glu4 (PTHWT, top; PTH7d, bottom) and 
receptor residues over triplicate simulations.  Raw data are connected by thin lines.  Second-order smoothened data 
(over 20 neighbors) are shown as thick lines. 
 
then structurally aligned the transmembrane domain (TMD) of rhodopsin from the rhodopsin-
visual-arrestin-1 crystal structure to the TMD of PTHWT ̶ PTHR after 200 ns simulation, followed 
by alignment of our βarr-1 model to visual-arrestin-1 (Fig. 14A).  In this model, residue Leu73 of 
βarr-1 engages in nonpolar interactions with TM6 residue Val412 of PTHWT-bound receptor (Fig. 
14A); however, the extended TM6 kink induced by PTH7d precludes these contacts by shifting 
Val412 of the receptor away from Leu73 of βarr-1 (Fig. 14A, 14B).  To confirm the ability of 
PTHWT to differentially promote interaction between Leu73 of βarr and the receptor, we performed 
photo-crosslinking experiments in cells transiently expressing PTHR and a photoreactive HA-
tagged βarr-1 analog in which residue Leu73 was substituted with p-benzoylphenylalanine (Bpa) 
(Fig. 14C).  This assay permits selective detection of Bpa73-dependent PTHR ̶ βarr1 complexes 
via co-immunoprecipitation and Western blot, as UV-induced covalent linkage of Bpa with the 
receptor is required to maintain the complex in the presence of sodium dodecyl sulfate (SDS).  In 
agreement with results from MD simulations and structural modeling, the Leu73Bpa βarr-1 mutant 
formed a complex with PTHR in response to PTHWT, but this effect was completely absent in cells 
treated with PTH7d compared to vehicle control (Fig. 14C).  Collectively, these data identify novel 
phosphorylation-independent, nonpolar contacts that are determinant for PTHR ̶ βarr interactions 
and provide the structural basis by which amino acid epimerization at position 7 of PTH leads to 
impaired βarr recruitment to the receptor. 
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Figure 14.  Structural basis for impaired βarr coupling by PTH7d.   
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(a) Snapshots of PTHWT ̶ PTHR (dark green) and PTH7d ̶ PTHR (violet) MD simulations after 200 ns were aligned by 
receptor transmembrane helices.  A model of βarr-1 (slate blue) was positioned based on the structural alignment of 
rhodopsin (from rhodopsin-visual-arrestin-1) to PTHWT-bound PTHR.  The dashed box highlights potential 
interactions of PTHR TM6 residues Val412 with βarr-1 Leu73.  (b) Distance distributions between PTHR Val412 
CG1 and βarr Leu73 CD1 side chain atoms over triplicate MD simulations of PTHWT- and PTH7d-bound receptor.  
Raw data are shown as thin lines.  Second order smoothened data (over 20 neighbors) are shown as thick lines (top, 
distance data over 200 ns simulations; bottom, distance data over the last 30 ns of each simulation).  Distances greater 
than 5.5 Å (red dashed line) prevent nonpolar interactions.  (c) Photo-crosslinking between βarr-1 Leu73Bpa and 
PTHR (left, schematic procedure; right, co-immunoprecipitation of HA-tagged βarr-1 Leu73Bpa and photo-
crosslinked PTHR  ̶ βarr-1 complexes.  Samples were immunoprecipitated and immunoblotted using an anti-HA 
antibody. 
 
 The PTHR is the main regulator of bone remodeling and serum mineral-ion (inorganic 
phosphate and Ca2+) homeostasis [54].  Despite previous reports demonstrating ligand-dependent 
modulation of these physiological processes, whether the location or the duration of the cAMP 
response is determinant remains unclear.  We thus compared the effects of PTH7d, PTHWT, and 
LA-PTH on these parameters in mice following four weeks of daily injection (40 µg/kg body 
weight).  Examination of skeletal parameters via micro-computed tomography (Fig 15A) further 
highlighted the physiological significance of spatial organization in PTHR-mediated signaling.  
While all three ligands caused expansion of metaphysis at their distal femurs (Fig. 15B, TV), only 
PTHWT and LA-PTH led to a significant increase in trabecular (Tb) bone fractions (Tb.BV/TV) 
and thickness (Tb.Th) when compared to vehicle control (Fig. 15B).  Additionally, LA-PTH 
treatment resulted in an increase in trabecular number (Tb.N) that was markedly distinct from that 
observed for PTH and PTH7d (Fig. 15B).  Analysis of effects on mineral-ion homeostasis revealed 
that each ligand caused similar reductions in serum Pi levels (Fig. 15C, top panel) consistent with 
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the previously reported regulation of phosphate uptake by PKA-dependent phosphorylation 
NHERF1 in the cytoplasm [152], while acute elevations in serum Ca2+ levels occurred only in 
response to PTHWT and LA-PTH, but not PTH7d, when compared to vehicle control (Fig. 15C, 
bottom panel).  In addition to direct effects on bone remodeling and Ca2+ homeostasis, previous 
studies have established that PTHR ligands can indirectly influence these processes via 
upregulation of the 25-hydroxyvitamin D 1-α hydroxylase [referred to as 1-α(OH)ase], the rate-
limiting enzyme that catalyzes the conversion of 25-hydroxyvitamin D to the active form of 
vitamin D (1,25D) in renal cells [153].  Our previous report that endosomal cAMP production 
enhances and prolongs phosphorylation and activation of the downstream transcription factor 
cAMP response element binding protein (CREB), coupled with observations that PTHR-mediated 
upregulation of 1-α(OH)ase occurs in a cAMP/PKA/CREB-dependent manner, led us to 
hypothesize that the impaired actions of PTH7d compared to PTHWT and LA-PTH arise from 
deficient nuclear cAMP/PKA signaling and thus reduced alterations in 1-α(OH)ase expression and 
circulating 1,25D.  Indeed, consistent with previous studies showing that cAMP, rather than PKA, 
diffusion into the nucleus represents the rate-limiting step for nuclear PKA activation [58, 154], 
we found that cAMP accumulates and activates PKA in the nucleus more efficiently over time 
when it originates from endosomes compared to the cell surface (Fig. 15D, 15E).  Additionally, 
we determined that basolateral stimulation with LA-PTH, but not PTH7d, caused a significant 
increased in expression of 1-α(OH)ase in polarized MDCK cells (Fig. 15F, 15G).  Remarkably 
consistent with this result was the sustained increase in circulating 1,25D upon injection of LA-
PTH into mice that was completely absent in mice treated with PTH7d (Fig. 15H).  Importantly, 
pharmacokinetic analysis of serum from mice treated with LA-PTH or PTH7d confirmed that 
biological effects were not influenced by differential degradation of these peptides (Fig. 16).   
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Figure 15.  Differential physiological actions of PTH7d, PTHWT, and LA-PTH in mice. 
(a,b) 3-D reconstructed µCT images (a) and quantifications of skeletal parameters in 
trabecular (Tb) bone of distal femur (b), including:  TV, Tb total volume; Tb.BV/TV, Tb bone 
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fraction over total bone volume; Tb.N, Tb number; and Tb.Th, Tb thickness.  Parameters were 
assessed in mice subjected to 4-week daily injections of PTH7d, PTHWT, LA-TPh, or vehicle (Veh) 
as described in panels (a) and (b).  N = 7 mice/group for PTH7d and PTHWT injections and N = 14 
mice/group for LA-PTH and Veh injections.  Data are the mean ± s.e.m. (*P < 0.05; ***P < 0.01; 
and ****P < 0.0001 vs Veh control mice by one-way ANOVA with Dunnett test).  (c) Serum 
phosphate (top panel) and Ca2+ (bottom panel) levels were measured 2 hours after the last of the 
4-week daily injections of PTH7d, PTHWT, and LA-PTH (40 µg/kg body weight/injection) or 
vehicle (Veh).  N = 7 mice/group; mean ± s.e.m. (*P < 0.05; **P < 0.01; and ****P < 0.0001 vs 
Veh control mice by one-way ANOVA with Dunnett test).  (d,e) Averaged time courses and 
integrated responses of nuclear cAMP (h) and PKA activation (i) in response to 30 nM LA-PTH 
or PTH7d.  Data are the mean ± s.e.m. of N = 3 independent experiments with n = 10-28 cells per 
experiment (**P = 0.009 and 0.008 for panels for panels d and e, respectively).  (f,g) 
Representative Western blot showing 1-α(OH)ase levels (top) in polarized PTHR-expressing 
MDCK cells after basolateral stimulation with either LA-PTH or PTH7d for 4 or 8 hours.  GAPDH 
was used as loading control.  Quantification of three independent Western blot experiments is 
shown in the bottom panel.  1-α(OH)ase levels were normalized to GAPDH levels (bottom).  Graph 
shows individual data points and mean ± s.e.m. (*P = 0.0195; **P = 0.003; and ***P = 0.0004 by 
one-way ANOVA with Tukey test.  (h) In a separate time-course study, serum 1,25D levels were 
measured in mice before or 1, 2, 4, 8, 12, or 24 hours after a single injection of PTH7d or LA-PTH.  
N = 7 mice/time point/drug and 14 mice for time “0” controls.  Mean ± s.e.m. (****P < 0.0001 vs 
time “0” controls by two-way ANOVA with Dunnett test). 
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Figure 16. Pharmacokinetic Analysis of PTH7d and LA-PTH. 
Blood plasma was assessed for LA-PTH or PTH7d bioactive peptide content by applying 5 µL of plasma to GP2.3 
cells and measuring cAMP-dependent changes in luminescence.  Data are the mean ± s.e.m. of N=3 experiments and 
n=5 mice per time point for each ligand. 
 
4.4 Discussion 
Previous studies have proposed a paradigm whereby the duration of the cAMP response 
serves as the sole determinant for PTHR-mediated regulation of serum Ca2+ and bone remodeling, 
and this model has served as the premise for the development of therapeutics targeting the receptor 
[155].  Our findings reveal that a shift in spatial bias of cAMP signaling from endosomes to the 
cell surface is sufficient to abolish PTH-induced effects on serum Ca2+ elevation, vitamin D 
activation, and bone formation, without alteration of serum Pi reduction. 
 The present work identifies that amino acid epimerization at a single position in a GPCR 
peptide ligand may provide a means to exquisitely probe ligand-dependent signaling determinants 
and physiological consequences, without significantly altering ligand binding affinity or stability 
in vivo.  In the case of PTH7d, L→D isomerization at position 7 of PTH revealed significant 
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modulation of PTHR  ̶βarr interactions and thus a shift in the cellular localization of sustained 
cAMP signaling from endosomes to the plasma membrane.  The formation of ternary PTHR-βarr-
Gβγ complexes and their translocation to early endosomes permits a prolonged phase of cAMP 
signaling from this intracellular compartment, and it is this response that is considered the primary 
determinant for driving distinct biological outcomes; however, sustained G protein-independent 
signaling by βarrs (e.g. ERK phosphorylation) in early endosomes has been reported.  Thus, it 
remains possible that the differences observed in this study between PTH7d and PTHWT/LA-PTH 
may involve βarr signaling that occurs independently of G proteins, an intriguing hypothesis to 
probe in future investigations. 
 Our study also raises the prospect of selectively modulating mineral-ion levels when there 
are pathophysiological aberrations.  For example, chronic kidney disease and poorly controlled 
diabetes have been shown to cause hyperphosphatemia [156].  PTH7d may prove useful 
therapeutically in this setting, as it possesses the ability to selectively reduce systemic phosphate 
levels without concomitant effects on serum Ca2+ and bone remodeling observed for traditional 
PTHR ligands.  In addition to the PTHR, several other GPCRs have been reported to engage in 
cAMP signaling from intracellular compartments, including the vasopressin type 2 receptor (V2R) 
[157], glucagon-like peptide 1 receptor (GLP-1R) [158], the β1-adrenergic receptor (β1AR) [159], 
among others, each of which hold potential biological and clinical significance:  the V2R is a major 
regulator of water homeostasis via actions in the kidneys, and has been implicated in nephrogenic 
diabetes insipidus and heart failure; the GLP-1R is well-known to modulate insulin secretion from 
the pancreas and currently serves as a therapeutic target for the treatment of type 2 diabetes; and 
the β1AR contributes to a wide variety of physiological processes, including cardiac function and 
blood pressure, and currently represents a main therapeutic target for the treatment of hypertension 
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and heart failure.  This study thus presents interesting implications for other GPCRs that may aid 
understanding of human physiology and facilitate rational drug design in the future. 
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5.0 Gq/11-dependent Regulation of Endosomal cAMP Generation by Parathyroid Hormone 
Class B GPCR 
Chapter adapted from: Alex D. White, Frédéric G. Jean-Alphonse, Fei Fang, Karina A. Peña, Shi 
Liu, Asuka Inoue, Despoina Aslanoglou, Samuel H. Gellman, Evi Kostenis, Kunhong Xiao, and 
Jean-Pierre Vilardaga.  Gq/11-dependent regulation of endosomal cAMP generation by parathyroid 
hormone class B GPCR.  PNAS (in press 2020). 
 
A.D.W., F.J-A, F.F., K.A.P., D.A., Z.F., and K.X. performed and/or designed experiments.  E.K. 
and G.M.K. provided FR900359.  A.I. provided CRISPR cells.  S.L. and S.H.G. contributed 
reagents that led to the studies here.  Authors analyzed and discussed the data.  J.P.V. was 
responsible for the overall conceptual composition and supervision of the study and wrote the 
manuscript with A.D.W. 
 
5.1 Introduction 
The PTHR is a class B GPCR that mediates the biological effects of endogenous peptide 
ligands PTH and PTHrP [160].  While the receptor functions to regulate growth and development 
of various tissues in response to PTHrP, PTH-induced activation of the PTHR serves as a critical 
role in homeostatic control of systemic Ca2+ and phosphate levels, as well as bone remodeling 
[161].  Although both ligands exert their physiological effects via binding to the same receptor and 
subsequent activation of Gs/cAMP and Gq/Ca
2+ signaling pathways [91], PTH and PTHrP are 
distinguished by cAMP responses that differ markedly in duration and cellular localization [31, 
55].  Association of PTHrP with the receptor permits only transient cAMP production from the 
cell membrane that is consistent with the classical model of GPCR signaling [55].  The receptor is 
also capable of promoting sustained cAMP generation following internalization of highly stable 
PTH-PTHR complexes that remain active in early endosomes.  Furthermore, accumulating 
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evidence suggests that these differential modes of signaling may give rise to distinct biological 
outcomes.  For example, a recently identified point mutation in PTH (Arg25→ Cys) that abolishes 
endosomal signaling causes severe hypocalcemia in patients harboring this mutation [51, 52].  In 
agreement with this finding, injection of a long-acting PTH (LA-PTH) analog into mice causes 
prolonged hypercalcemic responses that correlate with the propensity to promote sustained cAMP 
from endosomes [36].  Despite significant advancements in identifying the physiological relevance 
of PTHR endosomal signaling, its underlying molecular mechanisms and regulation remain 
incompletely understood.   
 We recently reported on the development of Gs-biased PTH analogs that stimulate cAMP 
production but fail to engage in endosomal cAMP signaling due to impaired recruitment of βarrs 
[162].  Observation that these same ligands also show deficient Gq signaling as measured by 
reduced intracellular Ca2+ mobilization in HEK293 cells stably expressing PTHR (HEK-PTHR) 
led us to question whether Gq signaling serves as a regulator of PTHR-mediated endosomal cAMP 
responses. 
5.2 Materials and Methods 
5.2.1 Cell Culture and Transfection 
Cell culture reagents were obtained from Corning (CellGro).  Human embryonic kidney 
cells (HEK293; ATCC, Georgetown, DC) stably expressing the recombinant human PTHR were 
grown in selection medium (DMEM, 5% FBS, 1% penicillin/streptomycin, 500 µg/mL neomycin) 
at 37 °C in a humidified atmosphere containing 5% CO2.  Primary mouse calvarial osteoblast (Ob) 
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cells were isolated and cultured as described [58]; RPTEC were grown in DMEM/F12 
supplemented with 5 pM triiodo-L-thyronine, 10 ng/mL recombinant human epidermal growth 
factor, 25 ng/mL prostaglandin E1, 3.5 µg/mL ascorbic acid, 1 mg/mL insulin, 0.55 mg/mL 
transferrin, 0.5 µg/mL sodium selenite, 25 ng/mL hydrocortisone, 1% penicillin/streptomycin).  
For transient expression, cells were seeded on glass coverslips coated with poly-D-lysine in six-
well plates and cultured for 24 hours prior transfection with the appropriate cDNAs using Fugene-
6 (Promega) or Lipofectamine 3000 (Life Technologies) for 48-72 hours before experiments.  We 
optimized expression conditions to ensure the expression of fluorescently labeled proteins was 
similar in examined cells by performing experiments in cells displaying comparable fluorescence 
levels. 
5.2.2 Peptides and Chemicals 
PTH(1-34) and PTH(1-34)TMR were synthesized and characterized as previously described 
[44].  Forskolin (#344270) was purchased from EMD-Millipore.  FR900359 (known as UBO-QIC 
former commercial name) was extracted from Ardisia crenata following a previously published 
protocol [163]. 
5.2.3 Plasmids 
DNA constructs encoding for PTHRYFP, PTHRCFP, and βarr-2YFP were previously 
described by the Vilardaga lab [31, 41, 123].  βarr-1Rluc8 was provide by Dr. Zachary Freyberg 
(University of Pittsburgh); GαqYFP, Gβ1BiFC (Cer(1-158)-Gβ1) and Gγ2BiFC (CFP-(159-238)-Gγ2) 
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were a gift from Dr. Catherine Berlot and can be found in Addgene (#55782, #55707, and #55707, 
respectively); masGRK3ct was a kind gift from Dr. Nevin Lambert (Augusta University). 
5.2.4 Co-immunoprecipitation 
HEK293 cells stably expressing HA-PTHR and cultured on a 10-cm dish were pre-
incubated with serum-free DMEM ± 100 nM TGX-221, then stimulated with 100 nM PTH for 5 
minutes.  Cells were then washed with ice-cold PBS prior to cross-linking for 2 hours with 1 mM 
DSP (Covachem, #13301) in PBS at 4 °C.  The reaction was stopped by addition of 10 mM Tris-
HCl for 10 minutes and cell lysates were prepared using lysis buffer (1 % Triton X-100, 50 mM 
Tris-HCl pH 7.4, 140 mM NaCl, 0.5 mM EDTA) containing protease and phosphatase inhibitor 
(Roche, #11873580001).  Protein concentration was determined using BCA protein assay kit 
(ThermoFisher, #23225), and lysates were incubated with anti-HA agarose antibody beads (Sigma-
Aldrich; #A2095 clone HA-7) overnight at 4 °C.  Elution was done using LDS loading buffer (Life 
Technologies) and samples were loaded on 10% SDS gels, followed by transfer to nitrocellulose 
membranes.  We used antibodies against HA (Covance, clone 16B12), and βarr-1/2 (Cell 
Signaling; #4674 clone D24H9).  Immunoreactive bands were visualized with Luminata Forte 
(EMD Millipore) and autoradiography film. 
5.2.5 Time-course Measurements of cAMP Production and βarr Recruitment in Live Cells 
cAMP was assessed using FRET-based assays.  Cells were transiently transfected with the 
FRET-based biosensor Epac1CFP/YFP [61] for measuring cAMP.  Measurements were performed 
and analyzed as previously described [62].  In brief, cells plated on poly-D-lysine coated glass 
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coverslips were mounted in Atoofluor cell chambers (Life Technologies), maintained in a HEPES 
buffer containing 150 mM NaCl, 20 mM HEPES, 2.5 mM KCl, 0.1-10 mM CaCl2, 0.1% BSA, 
and pH 7.4 and transferred on the Nikon Ti-E equipped with an oil immersion 40X numerical 
aperture 1.30 Plan Apo objective and a moving stage (Nikon Corporation).  CFP and YFP were 
excited using a mercury lamp.  Fluorescence emissions were filtered using a 480 ± 20 nm (CFP) 
and 535 ± 15 nm (YFP) filter set and collected simultaneously with a LUCAS electron-multiplying 
charge-coupled device camera (Andor Technology) using a DualView 2 (Photometrics) with a 
beam splitter dichroic long pass of 505 nm.  Fluorescence data were extracted from a single cell 
using Nikon Element Software (Nikon Corporation).  The FRET ratio for single cells was 
calculated and corrected as previously described [63].  Individual cells were perfused with buffer 
or with ligand for the time indicated by the horizontal bar.   
5.2.6 Saturation and Competition Binding at Equilibrium 
HEK293 cells were transiently transfected with HA-PTHR and seeded in 96-well plates. 
Approximately 48 h after transfection, cells were incubated in HEPES buffer (137 mM NaCl/5 
mM KCl/1 mM MgCl2/20 mM HEPES/0.1% BSA pH 7.4) for 1 h at 4 °C, followed by 2 h 
incubation at 4 °C in the presence of ligand. Increasing concentration of TMR-labeled PTH 
(PTHTMR) were utilized for saturation binding, while competition binding experiments used a 
constant PTHTMR concentration (31.6 nM) with increasing amounts of unlabeled PTH. Cells were 
washed twice with the same buffer, and fluorescence intensities were recorded at 580 ± 20 nm 
using an excitation wavelength of 525 ±20 nm on a Tecan Spark 20M multimode microplate 
reader. Nonspecific binding was determined using 1 μM of unlabeled ligand. Data were 
subsequently analyzed using Graphpad Prism 7.0 (GraphPad Software Inc., La Jolla, CA). 
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5.2.7 Laser Scanning Confocal Microscopy 
Cells plated on coverslips were mounted in Attofluor cell chambers (Life Technologies) 
and incubated with HEPES buffer (150 mM NaCl, 20 mM HEPES, 2.5 mM KCl, varied [Ca2+], 
0.1% BSA, pH 7.4) and transferred on the Nikon Ti-E microscope (Nikon) equipped with a Z-
driven piezo motor.  Imaging was performed using Nikon A1 confocal unit, through a 60X N.A. 
= 1.45 objective (Nikon).  Fluorescent antibody (anti-HA-Alex488, Cell Signaling, #2350), 
proteins or peptides containing CFP, Turqoise, GFP, FITC, YFP, tetramethylrhodamine (TMR) 
were excited with 440 nm (CFP, Turquoise), 488 nm (Alexa488, GFP, FITC), 514 nm (YFP) or 
561 nm (TMR) lasers (Melles Griot).  Data acquisitions were done using Nikon Element Software 
(Nikon Corporation).  After acquisition, raw data were analyzed using ImageJ software.  Each 
different analysis was done at the single-cell level. 
5.2.8 BRET Recordings of PTHR-βarr Interaction. 
HEK293 cells were transiently transfected with βarr-1Rluc8 and PTHRYFP and seeded in 96-
well plates.  Approximately 48 hours after transfection, cells were incubated in HEPES buffer (137 
mM NaCl/5 mM KCl/1 mM MgCl2/20 mM HEPES/0.1% BSA pH 7.4) at 37 °C in the presence 
of 5 µM coelenterazine-h for 10 minutes, followed by addition of increasing concentrations of 
PTH.  Donor and acceptor luminescence (466 and 535 nm, respectively) were measured at 2.5-
minute intervals using a Tecan Spark 20M multiplate reader.  For each well, the maximum 
luminescence observed, which typically occurred 10 minutes after PTH stimulation, was utilized 
to calculate BRET ratios (acceptor/donor).  Data were subsequently analyzed using Graphpad 
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Prism 7.0 (GraphPad Software Inc., La Jolla, CA) and expressed as ΔBRET, which was 
determined by subtracting ratios obtained in control wells containing cells with donor alone. 
5.2.9 Statistical Analysis 
Data were processed using Excel 2013 (Microsoft Corp. Redmon, WA) and Prism 7.0 
(GraphPad Software Inc. La Jolla, CA).  Data are expressed as mean ± SEM.  Curves were fitted 
to the data using a four-parameter, non-linear regression function.  Statistical analyses were 
performed using unpaired, 2-tailed Student’s t tests for comparisons between 2 groups. 
 
5.3 Results 
In support of this hypothesis, the selective Gq/11 inhibitor FR900359 markedly decreased the 
duration of PTH-induced cAMP responses in HEK-PTHR cells (Fig. 17A), and this effect was 
recapitulated in bone and kidney cells endogenously expressing the receptor (Fig. 17B-D).  Similar 
effects were observed on cAMP generation using another Gq/11 inhibitor, GP2A (Fig. 17E), as well 
as in HEK293 cells lacking Gαq/11 (HEK-Gq/11KO) (Fig. 17F).  Inhibition of the Gq/11 downstream 
effector PLC by U73122 had no effect on PTH-induced cAMP (Fig. 17G), thus these results 
collectively demonstrate that Gq/11 activation, as opposed to PLC-dependent signaling, is 
determinant for endosomal PTHR cAMP generation. 
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Figure 17. Gq/11-dependent cAMP Production by PTH. 
(A) Time courses of cAMP production recorded by FRET in response to 10 nM PTH in single HEK-PTHR cells +/- 
FR900359. (B-D) Similar assay as in panel A in response to 100 nM PTH in primary osteoblasts isolated from mice 
(B), rat osteosarcoma (ROS) 17/2.8 cells (C), and renal proximal tubular epithelial cells (RPTEC) (D). (E-H) Similar 
as in panel A +/- GP2A €, in parental and HEK-Gq/11KO cells (F), and as in panela A with the PLC inhibitor U73122 
(G), or in the absence (control) or presence of masGRK3ct (H).  cAMP data represent mean values ± SEM of N=3-4 
independent experiments and n=15-45 cells per experiment. (I) Fluorescence micrographs corresponding to the 
individual and merged channel data of HEK cells co-transfected with GβγCFP (cyan) and either GαqYFP or PTHRYFP 
(red).  Images were recorded at 30 second intervals for 15 minutes after a brief challenge with 100 nM PTH.  Scale 
bar = 10 µm. 
 
 To delineate the roles of Gα and Gβγ subunits in Gq/11-mediated regulation of cAMP, we 
utilized live-cell confocal microscopy to monitor the localization of fluorescently-labeled G 
protein subunits.  Under basal conditions, both GαqYFP and GβγCFP were observed primarily at the 
plasma membrane along with a small fraction located in subcellular compartments (Fig. 17I); 
however, brief stimulation with PTH induced translocation of Gβγ intracellularly that colocalized 
with the receptor, while Gαq remained at the cell surface (Fig. 17I).  Subsequent cAMP time-
course experiments revealed that translocation of Gβγ originating from the cell surface is critical 
for endosomal signaling, as expression of masGRK3ct, a Gβγ scavenger that localizes exclusively 
to the plasma membrane [164], completely abolished sustained signaling induced by PTH (Fig. 
17H).  We reasoned that Gq/11 activation, via provision of Gβγ subunits, may promote assembly of 
signaling complexes at the cell surface comprised of receptor, βarr, and Gβγ that have previously 
been reported as key components of PTHR-mediated endosomal cAMP production [36].  Indeed, 
time-course experiments measuring FRET between βarr-2YFP and either GβγCFP or PTHRCFP in 
response to PTH showed significantly impaired interactions in HEK-Gq/11
KO cells compared with 
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the parental cell line (Fig. 18A, 18B).  The unexpected effect of Gq/11 activation on βarr recruitment 
was confirmed in subsequent BRET-based assays using PTHRYFP and βarr-1Rluc8, which showed 
reduced potency (EC50) of PTH-induced recruitment of βarr in HEK-Gq/11KO (19.2 ± 0.44 nM) 
compared to parental cells (6.95 ± 0.44 nM) (Fig. 18C).  Consistent with data obtained for cAMP 
responses, additional FRET recordings showed that the reduced interaction between PTHR and 
βarr is not due to lack of PLC activity (Fig. 18D), but rather the availability of liberated Gβγ 
subunits at the cell surface derived from heterotrimeric Gq/11 proteins (Fig. 18E).   
The well-established ability of Gβγ to activate class I PI3K isoforms PI3Kβ/γ [165] coupled 
to the previously reported enhanced binding affinity of βarrs for phosphatidylinositol-(3,4,5)-
triphosphate (PtdIns(3,4,5)P3) compared to PtdIns(4,5)P2 led us to hypothesize that βarr coupling 
to the PTHR may be regulated by activation of Gq/11 heterotrimeric proteins through liberation of 
Gβγ subunits and subsequent activation of class I PI3K.  We tested this possibility using the PI3K 
inhibitor wortmannin in time-course experiments measuring βarr interaction by FRET between 
PTHRCFP and βarr-2YFP in response to PTH.  Indeed, we observed significantly slower kinetics and 
decreased magnitude of βarr-2 association with the receptor in wild-type HEK293 cells pre-
incubated with wortmannin compared to control cells (Fig. 19A, 19B); however, this effect was 
completely abolished in analogous experiments performed in HEK-Gq/11
KO cells (Fig. 19A).  Due 
to the relative non-selectivity of wortmannin, we repeated these experiments using the PI3Kβ-
specific inhibitor TGX-221 [166], which similarly reduced βarr recruitment to the PTHR in wild-
type but not Gq/11
KO cells (Fig. 19C).  Furthermore, the effect of TGX-221 on PTHR ̶ βarr 
interactions in wild-type cells was confirmed by co-immunoprecipitation assays (Fig. 19D).   
Consistent with a role in endosomal signaling, wortmannin and TGX-221 also markedly reduced 
the duration of PTH-induced cAMP responses in wild-type cells (Fig. 19E, 19F).  Altogether,  
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Figure 18.  Effect of Gq/11 Activation on the Formation of PTHR Endosomal Signaling Complexes. 
(A,B) Time-course experiments measuring FRET between βarr-2YFP and either GβγCFP (A) or PTHRCFP (B) in response 
to 10 nM PTH in wild-type (WT) HEK293 cells or cells lacking Gαq/11 (Gq/11KO).  Data represent the mean value ± 
SEM of N = 3 experiments and n = 17-31 cells per experiment (*P < 0.05; **P < 0.01). (C) Recruitment of βarr to the 
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PTHR as a function of PTH concentration measured by BRET in cells co-transfected with βarr-1Rluc8 and PTHRYFP.  
Data represent the mean ± SEM of N=3 experiments. (D) Similar experiments as in panels A and B with the PLC 
inhibitor U73122.  Data represent the mean value ± SEM of N=3 experiments and n=23-30 cells per experiment. (E) 
Effect of masGRK3ct on βarr recruitment to the receptor upon exposure to 10 nM PTH +/- FR900359 in cells 
transfected with PTHRCFP and βarr-2YFP.  Data represent the mean value ± SEM of N=3 experiments and n=16-18 
cells per experiment (****P < 0.0001). 
 
 
these results provide evidence that Gq/11-dependent PI3K activation via Gβγ represents a major 
mechanism for both the kinetics and magnitude of βarr interaction with the PTHR, which, in turn, 
regulates endosomal cAMP signaling. 
 In addition to its lipid kinase function, PI3Kβ has been shown to phosphorylate effector 
proteins as well [167].  To differentiate lipid versus protein kinase actions of PI3Kβ in mediating 
βarr recruitment, we utilized chemically-induced dimerization between FK506 binding protein 12 
(FKBP) and the FKBP12 rapamycin binding (FRB) domain of mTOR [168] to recruit PTEN to 
the plasma membrane.  PTEN is a lipid phosphatase that dephosphorylates predominantly 
PtdIns(3,4,5)P3, but also PtdIns(3,4)P2 to some extent, at the 3’ position [169].  By expressing 
mcherry-tagged PTEN-FKBP and FRB fused to the plasma membrane-targeting sequence Lyn11, 
addition of rapamycin results in acute depletion of PtdIns(3,4,5)P3 specifically at the plasma 
membrane (Fig. 19G, left).  We confirmed the efficacy of this approach using confocal imaging 
with cells co-expressing PTEN-FKBP-mcherry, Lyn11-FRB, and the venus-conjugated PH domain 
from Akt (PH-Akt-venus) that binds selectively to the 3’-phosphate of PtdIns(3,4,5)P3 [169].  
Under basal conditions, PH-Akt-venus localized almost exclusively at the plasma membrane, but 
rapidly translocated to the cytoplasm upon addition of rapamycin (Fig. 19G, middle and right).  
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Figure 19.  Recruitment of βarr is Regulated by Gq/11-dependent Activation of PI3Kβ. 
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We subsequently used this system in FRET-based time courses of βarr recruitment, which revealed 
a significant reduction in PTHR ̶ βarr interactions in the presence of rapamycin in cells expressing 
wild-type PTEN (PTENWT) but not in those expressing a catalytically dead mutant of PTEN 
(PTENC124S) [170] (Fig. 19H).  Taken together, these findings suggest that Gq/11-dependent 
generation of PtdIns(3,4,5)P3 by PI3Kβ at the plasma membrane serves as a critical regulator of 
βarr recruitment to the PTHR and thus the propensity of the receptor to engage in endosomal 
cAMP signaling in response to PTH. 
5.4 Discussion 
Initially thought to induce signaling exclusively from the plasma membrane, several 
GPCRs are now recognized for eliciting responses from intracellular compartments, including the 
Golgi apparatus [159] and endosomes [55].  Notably, studies involving the class B PTHR have 
shown that binding of PTH causes sustained cAMP responses attributed to ligand-receptor 
complexes that remain active in early endosomes following βarr-mediated internalization.  
Accordingly, endosomal cAMP responses are thus considered to be regulated by Gs- and βarr-
dependent signaling pathways.  While the PTHR also activates Gq/11 in response to PTH, the role 
of this pathway in endosomal cAMP generation has been ignored because of its foremost 
association with the PLC/Ca2+ pathway.  Mechanistically, our findings unveil that Gq/11 promotes 
PI3Kβ-mediated generation of PtdIns(3,4,5)P3 (PIP3) at the plasma membrane and that this 
represents a critical determinant for association of βarr with the PTHR.  Further understanding of 
how PIP3 can be used to promote the association between arrestin and PTHR will require, for 
example, structural studies to determine whether PIP3 directly binds to the PTHR to stabilize a 
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functional active state that favors formation of the PTHR ̶ arrestin complex.  Another question to 
be explored is whether the PIP3-dependent recruitment of arrestin is restricted to either the PTHR 
or receptors with Gs/Gq/11 signaling pleiotropy, such as class B GPCRs.  This is particularly 
pertinent given that PIP3 was previously reported to have no effect on βarr recruitment to the class 
A β2-adrenergic receptor [171].  Thus, future investigations into other receptors that couple to Gq/11 
and engage in sustained cAMP signaling from intracellular compartments may provide insight into 
the breadth of PIP3-mediated regulation of GPCR ̶ βarr interactions.  Collectively, our findings 
identify a regulatory mechanism of PTH-induced cAMP wherein Gq/11-derived Gβγ subunits 
enhance the assembly of ternary PTHR-βarr-Gβγ complexes at the cell surface, which permits 
endosomal cAMP generation.  While previous studies have implicated Gβγ-dependent modulation 
of adenylyl cyclase activity in the context of receptor functional crosstalk [58], our results provide 
a novel instance of a single GPCR that utilizes Gq/11-dependent formation of signaling complexes 
to control the spatial organization and duration of Gs-mediated cAMP production. 
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6.0 Final Conclusions 
Since initial reports of the PTHR as a GPCR that deviates from the classical signaling 
paradigm, significant efforts have been made to elucidate the molecular mechanisms underlying 
the receptor’s ligand-specific spatiotemporal regulation of cAMP signaling, as well as its 
biological and disease relevance.  Herein we investigated the role of extracellular Ca2+ 
concentration in PTHR-mediated cAMP responses and identified this divalent cation as a positive 
allosteric modulator that increases the propensity of PTH to engage in endosomal signaling (Fig. 
21).  We determined that Ca2+ allostery is coordinated by ECL1 residues of the receptor and R25 
of PTH, and further demonstrated that loss of sensitivity to Ca2+ for the hypocalcemia-associated 
R25C mutant results in ablation of endosomal cAMP generation (Fig. 21).  We subsequently 
presented the development of Gs-biased PTHR ligands that enabled evaluation of the biological 
information encoded in the spatial versus temporal dimension of cAMP signaling (Fig. 21).  We 
found that sustained cAMP specifically from endosomes is required for PTH-mediated regulation 
of serum Ca2+, vitamin D activation, and particular aspects of bone remodeling processes (Fig. 
21).  We then probed the role of Gq/11 signaling in PTH-induced endosomal cAMP, and 
demonstrated that Gq/11-derived Gβγ subunits at the cell surface act in a PI3K-dependent manner 
to promote the assembly of signaling complexes compatible with sustained cAMP generation from 
endosomes (Fig. 22).  These findings will provide key insights toward understanding PTHR 
signaling and biology, as well as rational drug design. 
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Figure 20. Ca2+ Allostery in PTHR Signaling. 
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Figure 21. Decoding Spatial From Temporal Information of cAMP Signaling via PTH Receptor Biased 
Agonism. 
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Figure 22. Gq/11-dependent Regulation of Endosomal cAMP Generation by PTH Class B GPCR.  
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